<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003385" GROUP_ID="DEPRESSN" ID="831400070810004584" MERGED_FROM="" MODIFIED="2010-02-25 12:13:13 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2&lt;br&gt;Short title (no longer in use): Antidepressants and psychotherapies for BN&lt;/p&gt;&lt;p&gt;&lt;br&gt;Old title: - TSC OK - AWAITING REVIEWER OK - Antidepressants versus psychological treatments and their combination for bulimia nervosa&lt;/p&gt;" NOTES_MODIFIED="2010-02-25 12:13:13 +0000" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="051" REVMAN_SUB_VERSION="5.0.23" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="14.0">
<COVER_SHEET MODIFIED="2010-02-25 12:11:10 +0000" MODIFIED_BY="Jane Dennis">
<TITLE>Antidepressants versus psychological treatments and their combination for bulimia nervosa</TITLE>
<CONTACT>
<PERSON ID="13124" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Angélica</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Claudino</LAST_NAME>
<SUFFIX/>
<POSITION>Visiting Fellow</POSITION>
<EMAIL_1>angelica.claudino@uol.com.br</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Section of Eating Disorders, PO Box 59</DEPARTMENT>
<ORGANISATION>Institute of Psychiatry, King's College London</ORGANISATION>
<ADDRESS_1>De Crespigny Park</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>SE5 8AF</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 20 7848 0653</PHONE_1>
<PHONE_2>+44 20 7848 0183</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2010-02-25 12:11:10 +0000" MODIFIED_BY="Jane Dennis">
<PERSON ID="17006" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Phillipa</FIRST_NAME>
<MIDDLE_INITIALS>PJ</MIDDLE_INITIALS>
<LAST_NAME>Hay</LAST_NAME>
<SUFFIX/>
<POSITION>Foundation Chair</POSITION>
<EMAIL_1>p.hay@uws.edu.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Mental Health School of Medicine</DEPARTMENT>
<ORGANISATION>Building 3</ORGANISATION>
<ADDRESS_1>Campbelltown Campus University of Western Sydney</ADDRESS_1>
<ADDRESS_2>Locked Bag 1797</ADDRESS_2>
<CITY>Penrith South</CITY>
<ZIP>2570</ZIP>
<REGION>New South Wales</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+ 61 2 98524668</PHONE_1>
<PHONE_2/>
<FAX_1>+61 2 98524702</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13124" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Angélica</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Claudino</LAST_NAME>
<SUFFIX/>
<POSITION>Visiting Fellow</POSITION>
<EMAIL_1>angelica.claudino@uol.com.br</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Section of Eating Disorders, PO Box 59</DEPARTMENT>
<ORGANISATION>Institute of Psychiatry, King's College London</ORGANISATION>
<ADDRESS_1>De Crespigny Park</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>SE5 8AF</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 20 7848 0653</PHONE_1>
<PHONE_2>+44 20 7848 0183</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5BB919C682E26AA2004F2C1CB78124BB" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Marcel</FIRST_NAME>
<MIDDLE_INITIALS>H</MIDDLE_INITIALS>
<LAST_NAME>Kaio</LAST_NAME>
<SUFFIX/>
<POSITION>Medical Director of Day Hospital CAPS Itapeva ? linked to Proata/UNIFESP</POSITION>
<EMAIL_1>marcel.higa@terra.com.br</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Psychiatry - Proata - Eating Disorders Program</DEPARTMENT>
<ORGANISATION>Federal University of Sao Paulo - UNIFESP</ORGANISATION>
<ADDRESS_1>Rua Capote Valente 439 Cj 73 CEP</ADDRESS_1>
<ADDRESS_2/>
<CITY>Sao Paulo</CITY>
<ZIP>05409-000</ZIP>
<REGION/>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>55-11-3081-2119</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-11-11 20:14:50 +0000" MODIFIED_BY="Rachel Churchill" NOTES="&lt;p&gt;Minor update: 25/02/05&lt;/p&gt;" NOTES_MODIFIED="2008-11-11 20:14:50 +0000" NOTES_MODIFIED_BY="Rachel Churchill">
<UP_TO_DATE>
<DATE DAY="13" MONTH="8" YEAR="2001"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="13" MONTH="8" YEAR="2001"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="4" MONTH="2" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="1997"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2001"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="1" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="13" MONTH="8" YEAR="2001"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-02-25 12:12:52 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-11-11 20:20:34 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-11-11 20:16:17 +0000" MODIFIED_BY="[Empty name]">Antidepressants and psychological treatments, alone or combined, for bulimia nervosa</TITLE>
<SUMMARY_BODY MODIFIED="2008-11-11 20:20:34 +0000" MODIFIED_BY="[Empty name]">
<P>Psychotherapeutic approaches, mainly cognitive behavior therapy, and antidepressant medication are the two treatment modalities that have received most support in controlled outcome studies of bulimia nervosa. Using a more conservative statistical approach, combination treatments were superior to single psychotherapy. This was the only statistically significant difference between treatments. The number of trials might be insufficient to show the statistical significance of a 19% absolute risk reduction in efficacy favouring psychotherapy or combination treatments over single antidepressants. Psychotherapy appeared to be more acceptable to subjects. When antidepressants were combined with psychological treatments, acceptability of the latter was significantly reduced.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-11-11 20:20:58 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Psychotherapeutic approaches, mainly cognitive behavior therapy, and antidepressant medication are the two treatment modalities that have received most support in controlled outcome studies of bulimia nervosa.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>The primary objective was to conduct a systematic review of all RCTs comparing antidepressants with psychological approaches or comparing their combination with each single approach for the treatment of bulimia nervosa.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>(1) electronic searches of MEDLINE (1966 to December 2000), EMBASE (1980-December 2000) , PsycLIT (to December 2000), LILACS &amp; SCISEARCH (to 1999)<BR/>(2) the Cochrane Register of Controlled Trials and the Cochrane Depression, Anxiety and Neurosis Group Register - ongoing<BR/>(3) handsearches of the references of all identified trials<BR/>(4) contact with the pharmaceutical companies and the principal investigator of each included trial<BR/>(5) handsearch of the International Journal of Eating Disorders - ongoing</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Inclusion criteria: every randomized controlled trial in which antidepressants were compared with psychological treatments or the combination of antidepressants with psychological approaches was compared to each treatment alone, to reduce the symptoms of bulimia nervosa in patients of any age or gender. <BR/>Quality criteria: reports were considered adequate if they were classified as A or B according to the Cochrane Manual.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Data were extracted independently by two reviewers for each included trial. The main outcome for efficacy was full remission of bulimic symptoms, defined as 100% reduction in binge or purge episodes from baseline to endpoint. Dichotomous data was evaluated by the relative risks and 95% confidence intervals around this measure, based on the random effects model; continuous data was evaluated by the average difference and the 95% confidence interval. Number needed to treat (NNT) and number needed to harm (NNH) were calculated using the inverse of the absolute risk reduction.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Five trials were included in comparison one (antidepressants versus psychological treatments), five in comparison two (antidepressants versus the combination) and seven in comparison three (psychological treatments versus the combination). Remission rates were 20% for single antidepressants compared to 39% for single psychotherapy (DerSimonian-Laird Relative Risk = 1.28; 95% Confidence Interval = 0.98;1.67). Dropout rates were higher for antidepressants than for psychotherapy (DerSimonian-Laird Relative Risk = 2.18; 95% Confidence Interval = 1.09;4.35). The NNH for a mean treatment duration of 17.5 weeks was 4 (95% confidence interval = 3;11). Comparison two found remission rates of 42% for the combination versus 23% for antidepressants (DerSimonian-Laird Relative Risk = 1.38; 95% Confidence Interval = 0.98;1.93). Comparison three showed a 36% pooled remission rate for psychological approaches compared to 49% for the combination (DerSimonian-Laird Relative Risk = 1.21; 95% Confidence Interval = 1.02;1.45). The NNT for a mean treatment duration of 15 weeks was 8 (95% Confidence Interval = 4;320). Dropout rates were higher for the combination compared to single psychological treatments (DerSimonian-Laird Relative Risk = 0.57; 95% Confidence Interval = 0.38;0.88). The NNH was 7 (95% Confidence Interval = 4;21).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-11-11 20:20:58 +0000" MODIFIED_BY="[Empty name]">
<P>Using a more conservative statistical approach, combination treatments were superior to single psychotherapy. This was the only statistically significant difference between treatments. The number of trials might be insufficient to show the statistical significance of a 19% absolute risk reduction in efficacy favouring psychotherapy or combination treatments over single antidepressants. Psychotherapy appeared to be more acceptable to subjects. When antidepressants were combined with psychological treatments, acceptability of the latter was significantly reduced.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-02-25 12:12:52 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>Bulimia Nervosa is an eating disorder characterized by recurrent episodes of uncontrolled compulsive eating binges, followed by compensatory behaviors to prevent weight gain. These behaviors include self-induced vomiting, the most frequent one, and misuse of laxatives, diuretics, enemas or other medications, fasting or excessive exercise. In addition, body shape and weight unduly influence self-evaluation of individuals with bulimia nervosa. Their self-esteem is regulated in the extreme by these aspects of their appearance. They feel in intense pressure to diet and to avoid weight gain (<LINK REF="REF-APA-1994" TYPE="REFERENCE">APA 1994</LINK>). At least 90% of individuals with bulimia nervosa are female. Surveys indicate that the prevalence among adolescent and young adult females is approximately 1% to 3% . </P>
<P>Treatments that have received the most support in controlled outcome studies of bulimia nervosa are psychotherapeutic approaches, mainly cognitive behavior therapy, antidepressant medications, and their combination (antidepressants plus psychological approaches). All types of antidepressants seem to be beneficial in the short-term in relieving bulimic symptoms (<LINK REF="REF-Wolfe-1995" TYPE="REFERENCE">Wolfe 1995</LINK>). Short-term abstinence rates (on average 8 weeks) are about 20%, and overall reductions in bulimic behaviors are about 70% (<LINK REF="STD-Agras-1992" TYPE="STUDY">Agras 1992</LINK>, <LINK REF="REF-Bacaltchuk-2000-a" TYPE="REFERENCE">Bacaltchuk 2000 a</LINK>, <LINK REF="STD-Leitenberg-1994" TYPE="STUDY">Leitenberg 1994</LINK>). However, a significant relapse rate (30-45%) is observed in patients followed for 4-6 months (<LINK REF="STD-Walsh-1997" TYPE="STUDY">Walsh 1997</LINK>). There is no clear evidence of a differential effect among the various classes of drugs used relative to placebo. However, there are two unpublished trials showing no benefit of fluvoxamine compared to placebo (<LINK REF="REF-Corcos-1996" TYPE="REFERENCE">Corcos 1996</LINK>). </P>
<P>Cognitive behavior therapy (CBT) is considered the standard treatment of choice for bulimia nervosa. The CBT model for bulimia nervosa was developed by Fairburn and colleagues (<LINK REF="REF-Fairburn-1991" TYPE="REFERENCE">Fairburn 1991</LINK>) and has the following major features: (1) self monitoring of food intake and of bingeing and purging episodes, as well as the thoughts and feelings that trigger these episodes; (2) regular weighing; (3) specific recommendations designed to normalize eating behavior and curb restrictive dieting; (4) cognitive restructuring directed at habitual reasoning errors and underlying assumptions that are relevant to the development and maintenance of the eating disorder; and (5) prevention of relapse. Numerous randomized controlled trials (RCTs) have shown that CBT is either significantly more effective or at least as effective as any alternative form of psychotherapy (<LINK REF="REF-Hay-2000" TYPE="REFERENCE">Hay 2000</LINK>). Nonetheless, CBT is underutilized, mainly due to the relative unavailability of therapists with specialized training in CBT for eating disorders in many countries.</P>
<P>This review assessed the effectiveness and acceptability of antidepressants compared with psychological treatments, including CBT, and of their combination compared to each single treatment, in bulimia nervosa.</P>
</BACKGROUND>
<OBJECTIVES>
<P>The objectives of this review were:</P>
<P>1. to investigate whether using antidepressant medications was clinically effective compared to psychological treatments for the treatment of bulimia nervosa. </P>
<P>2. to investigate whether using a combination of antidepressants plus psychological treatments was more effective compared to each single approach for the treatment of bulimia nervosa.</P>
<P>Where possible, a meta-analytic synthesis of the studies was performed.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>We attempted to identify all relevant randomized controlled trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>People with bulimia nervosa defined by clinical state description or diagnosed by Russell's (<LINK REF="REF-Russell-1979" TYPE="REFERENCE">Russell 1979</LINK>), DSM-III (<LINK REF="REF-APA-1980" TYPE="REFERENCE">APA 1980</LINK>), DSM-III-R (<LINK REF="REF-APA-1987" TYPE="REFERENCE">APA 1987</LINK>), DSM-IV (<LINK REF="REF-APA-1994" TYPE="REFERENCE">APA 1994</LINK>) or ICD-10 (<LINK REF="REF-WHO-1992" TYPE="REFERENCE">WHO 1992</LINK>) criteria, irrespective of gender, age or treatment setting. Participants with both purging and nonpurging type bulimia nervosa, as defined in DSM-IV (<LINK REF="REF-APA-1994" TYPE="REFERENCE">APA 1994</LINK>), were included. <BR/>Exclusion criteria: people with binge-eating/purging type anorexia nervosa or binge-eating disorder as defined in the DSM-IV (<LINK REF="REF-APA-1994" TYPE="REFERENCE">APA 1994</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Trials were included if they compared antidepressants with psychological treatments or their combination to each single approach during at least 4 weeks.</P>
<P>The following antidepressants were included:<BR/>a) tricyclic antidepressants (TCA):imipramine, amitryptiline, clomipramine, nortryptiline, desipramine;<BR/>b) selective serotonin reuptake inhibotors (SSRI): fluoxetine, sertraline, paroxetine, citalopram, fluvoxamine;<BR/>c) monoamine oxidase inhibitors (MAOI): phenelzine, isocarboxazide, moclobemide, brofaromine, tranylcipromine;<BR/>d) other antidepressants: bupropion, trazodone, nefazodone, mianserine, mirtazapine, venlafaxine.</P>
<P>The following individual or group, extensive or intensive psychological treatments were included:<BR/>i) cognitive-behavior therapy<BR/>ii) cognitive therapy<BR/>iii) behaviour therapy<BR/>iv) psychodynamic/psychoanalytic oriented therapy<BR/>v) interpersonal therapy<BR/>vi) supportive therapy<BR/>vii) family therapy<BR/>viii) nutritional counselling<BR/>ix) any other psychological approach not specified above</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>A. Efficacy<BR/>(i) the number of people per treatment group who did not show a remission in the bulimic symptoms, defined as 100% reduction in binge or purge episodes from baseline to endpoint<BR/>(ii) the number of people per treatment group who did not show a clinical improvement in the bulimic symptoms, defined as at least 50% reduction in binge or purge episodes from baseline to endpoint<BR/>(iii) the average difference in bulimic symptoms at endpoint</P>
<P>B. Comorbidity<BR/>(i) average difference in the severity of depressive symptoms at the end of the trial</P>
<P>C. Acceptability of the treatment<BR/>(i) number of people per treatment group dropping out during the trial for any cause</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>See: Collaborative Review Group search strategy<BR/>A. Electronic searching<BR/>Relevant randomized trials were identified by searching the following eletronic databases by means of the Depression, Anxiety and Neurosis Group Strategy (see CCDAN module):</P>
<P>(i) MEDLINE (January 1966 to December 2000). A subsection of this was obtained by linking the DAN search with the following specific search for this review:</P>
<P>[and ((bulimia in MeSH / explode all subheadings) or (binge*) or (overeating*) or (compulsive near (eating* or vomit*)) or (food* near bing*))]</P>
<P>This downloaded set of reports was searched for possible trials and re-searched, within the bibliographic package, ProCite, with the phrase:<BR/>[antidepressant* or tricyclic* or imipramine or amitryptiline or clomipramine or nortryptiline or desipramine or fluoxetine or sertraline or paroxetine or citalopram or fluvoxamine or bupropion or trazodone or nefazodone or phenelzine or isocarboxazid* or moclobemide or brofaromine or tranylcipromine or mianserin or mirtazapine]</P>
<P>(ii) EMBASE (January 1980 to December 2000) was searched by linking the DAN search with the phrase:</P>
<P>[and ((bulimia in theasurus - subheadings, prevention, drug therapy, side effect and therapy) or (binge*) or (overeating*) or (compulsive or eating* or vomit*) or (food* or binge*))]</P>
<P>This downloaded set of reports was searched for possible trials and re-searched, within the bibliographic package, ProCite, with the phrase:<BR/>[antidepressant* or tricyclic* or imipramine or amitryptiline or clomipramine or nortryptiline or desipramine or fluoxetine or sertraline or paroxetine or citalopram or fluvoxamine or bupropion or trazodone or nefazodone or phenelzine or isocarboxazid* or moclobemide or brofaromine or tranylcipromine or mianserin or mirtazapine]</P>
<P>(iii) LILACS (January 1982 to December 2000) DAN search was combined with the phrase:</P>
<P>[and (bulimia in theasurus)]</P>
<P>This downloaded set of reports was searched for possible trials and re-searched, within the bibliographic package, ProCite, with the phrase:<BR/>[antidepressant* or tricyclic* or imipramine or amitryptiline or clomipramine or nortryptiline or desipramine or fluoxetine or sertraline or paroxetine or citalopram or fluvoxamine or bupropion or trazodone or nefazodone or phenelzine or isocarboxazid* or moclobemide or brofaromine or tranylcipromine or mianserin or mirtazapine]</P>
<P>(iv) PsycLIT (January 1974 to December 2000) was searched combining the DAN search strategy for randomized controlled trials with the phrase:</P>
<P>[and ((explode bulimi* in DE) or (explode binge* in DE) or (overeating*) or (compulsive* near (eating* or vomit*) or (food* near binge*))]</P>
<P>This downloaded set of reports was searched for possible trials and re-searched, within the bibliographic package, ProCite, with the phrase:<BR/>[antidepressant* or tricyclic* or imipramine or amitryptiline or clomipramine or nortryptiline or desipramine or fluoxetine or sertraline or paroxetine or citalopram or fluvoxamine or bupropion or trazodone or nefazodone or phenelzine or isocarboxazid* or moclobemide or brofaromine or tranylcipromine or mianserin or mirtazapine]</P>
<P>(v) the Cochrane Depression, Anxiety and Neurosis Group Database of Trials</P>
<P>(vi) the Cochrane Controlled Trials Register was searched with the phrase:</P>
<P>[and ((bulimia in MeSH / explode all subheadings) or (binge*) or (overeating*) or (compulsive near (eating* or vomit*)) or (food* near bing*))]</P>
<P>(vii) SCISEARCH - Science Citation Index<BR/>Each of the included studies was sought as a citation on the SCISEARCH database. Reports of articles that had cited these studies were inspected in order to identify further trials.</P>
<P>(viii) Electronic search was performed by the CCDAN Group.</P>
<P>B. A second search was conducted with Clinical Evidence (HAY 2001) and comprised Medline 1966-December 2000, Embase 1980-December 2000, Psychlit 1989-December 2000.Cochrane 2000 Issue 4. The following terms were used: (bulimia or bulimia nervosa or eating disorders or binge eating) and (therapy or treatments or trials or psychotherapy or cognitive-behavioural therapy or pharmacotherapy or antidepressant or SSRI or MAOI).</P>
<P>C. Reference searching. The reference lists of all papers selected were inspected for further relevant studies.</P>
<P>D. Pharmaceutical companies. Companies carrying out comparative studies of their own products with placebo in the treatment of bulimia nervosa were contacted in order to obtain data on unpublished trials.</P>
<P>E. Personal contact. The first authors of all included studies were contacted for further information or information regarding unpublished trials.</P>
<P>F. A handsearch from the first issue of the International Journal of Eating Disorders is ongoing.The first authors of all included studies were contacted for further information or information regarding unpublished trials.</P>
<P>G. Book chapters on the treatment of bulimia nervosa were reviewed.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Selection of trials<BR/>The abstract of each reference identified by the search was evaluated by one reviewer (JB) in order to see if the study was likely to be relevant. For this review all trials comparing antidepressants with psychological treatments or combinations of antidepressant medications plus individual or group psychological treatments versus each single treatment were eligible, whether other comparisons were made in the trial or not. For possible RCTs the full article was obtained and inspected by two independent reviewers to assess whether they met criteria to be included. <BR/>Quality assessment<BR/>In order to ensure that variation was not caused by systematic errors in the design of a study, the methodological quality of the trials eligible to be included in this review was assessed by two independent reviewers. As randomization concealment has been shown to affect trial outcomes (<LINK REF="REF-Schultz-1995" TYPE="REFERENCE">Schultz 1995</LINK>), quality of trials was graded according to the three categories described in the Cochrane Handbook (<LINK REF="REF-Mulrow-1996" TYPE="REFERENCE">Mulrow 1996</LINK>). The Cochrane Collaboration Handbook criteria is based on the evidence of a strong relationship among potential for bias in the results and allocation concealment (<LINK REF="REF-Schultz-1995" TYPE="REFERENCE">Schultz 1995</LINK>, <LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>) and are defined as below:</P>
<P>A. Low risk of bias (adequate allocation concealment)<BR/>B. Moderate risk of bias (some doubt about the results)<BR/>C. High risk of bias (inadequate allocation concealment)</P>
<P>Trials included in this review were those with low or moderate risk of bias (category A or B, respectively). Randomized studies with no information on the allocation concealment process obtained from the authors were included in category B.</P>
<P>Reviewers were not blind to the names of the authors, institutions and journal of publication. Where disagreement could not be resolved by discussion and consensus, further information was sought contacting the authors for clarification. The articles were then added to the list of those awaiting assessment. The same adapted methodology was used for the selection of trials identified by means of reference lists searched and for data on unpublished trials obtained through the pharmaceutical industry or personal contacts with first authors. An inter-rater reliability study between reviewers for the Cochrane Collaboration Handbook grades was performed by means of the kappa.</P>
<P>Data Management<BR/>Data from the selected trials was extracted by the same two reviewers. Again, any disagreement was discussed, the decisions were documented and, if necessary, the authors of the studies were contacted for clarification. Justification for excluding references from the review was documented. It was antecipated that many trials would have an inadequate reporting. As the objective was to perform an intention-to-treat analysis, it was assumed a priori that dropouts would be assigned to the worst outcome (no remission or no improvement in their bulimic symptoms). </P>
<P>It was also expected that some trials would have used a crossover design. In order to exclude the potential additive effect in the second or more stages of these trials, only data from the first stage was analysed.</P>
<P>Analysis<BR/>Dichotomous outcomes (remission, clinical improvement and dropouts) were analysed by calculating relative risks (RR) and 95% confidence intervals (CI) for each trial. The RR from the individual trials were combined using appropriate methods of meta-analysis. The estimates of RR were based on the random effects model. This model takes into account both within-study sampling error and any between-studies variations in the assessment of the CI of the results (even if there was no statistically significant heterogeneity) and gives the same result as the fixed effects model when there is no between study variance. If the RR equaled 1, this indicated no difference between the groups compared. Additionally, when overall results were significant the number needed to treat statistics (NNT) was calculated by combining the RR with an estimate of the prevalence of the event in the control groups of the trials. The NNT indicates the number of patients who need to be treated to prevent one bad outcome and is the inverse of the absolute risk reduction. In the case of dropouts, the corresponding number needed to harm (NNH) was calculated. <BR/>For continuous outcomes the mean and standard deviations of these measures were assessed. They were analysed according to their difference in mean treatment effects and its standard differences, and standardised mean differences calculated. When appropriate, the raw data was log-transformed to improve the distribution of the data and for scales that had similar psychometric properties (for example range and scoring direction) these scores were entered in a meta-analysis.</P>
<P>Heterogeneity in the results of the trials, i.e., whether differences among the results were greater than would be expected by chance alone, was assessed both visually by inspection of graphical presentations and by calculating a chi-square test of heterogeneity. Finally, the possibility of publication bias was visually assessed from funnel graphs and the fail safe-N calculated (<LINK REF="REF-Hedges-1985" TYPE="REFERENCE">Hedges 1985</LINK>).</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-02-25 12:12:52 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2010-02-25 12:12:52 +0000" MODIFIED_BY="[Empty name]">
<P>Five trials fulfilled inclusion criteria and had evaluable data for at least one outcome of comparison one (237 patients in total). Five studies were also included in comparison two (247 patients, 124 randomised to antidepressants and 123 to the combination), and seven studies were included in comparison three (343 patients, 166 randomised to psychological treatments and 177 to the combination). Thirty-seven studies identified with the search strategy compared antidepressants with placebo, without a psychotherapy control group and/or were subset studies with follow-up or partial data. Therefore, they were not eligible for this review.</P>
<P>All studies were described as randomized. One (<LINK REF="STD-Walsh-1997" TYPE="STUDY">Walsh 1997</LINK>) compared sequential antidepressants (desipramine followed by fluoxetine 60 mg daily for those patients who did not improve after eight weeks on desipramine) to two types of psychotherapy: CBT and supportive therapy, alone and combined to an antidepressant (five comparison groups in total), for 16 weeks. Only the CBT combination group was considered, compared with the sequential antidepressants group (comparison two) or with the single CBT group (comparison three). One study (<LINK REF="STD-Mitchell-1990" TYPE="STUDY">Mitchell 1990</LINK>) compared imipramine 200 mg daily with intensive group CBT for 10 weeks, alone and in combination and one study (<LINK REF="STD-Leitenberg-1994" TYPE="STUDY">Leitenberg 1994</LINK>) compared desipramine 150 mg with individual CBT alone and in combination during respectively 20 weeks. Another study (<LINK REF="STD-Goldbloom-1996" TYPE="STUDY">Goldbloom 1996</LINK>) compared fluoxetine 60 mg daily to CBT or the combination over 16 weeks. The single antidepressant and the single CBT groups were considered in comparison one and the combined treatment groups in comparisons two or three. One trial (<LINK REF="STD-Agras-1992" TYPE="STUDY">Agras 1992</LINK>) compared desipramine sixteen and twenty-four weeks to CBT twenty-four weeks or to the combination of CBT twenty-four weeks plus desipramine sixteen or twenty-four weeks. Only the twenty-four week single desipramine, single CBT and combination groups were considered. The sixth study (<LINK REF="STD-Fichter-1991" TYPE="STUDY">Fichter 1991</LINK>) compared the combination of fluoxetine 60 mg daily plus inpatient intensive therapy with inpatient intensive therapy plus placebo over 5 weeks. The seventh study (<LINK REF="STD-Russell-1995-b" TYPE="STUDY">Russell 1995 b</LINK>) compared fluoxetine 60 mg daily plus nutritional counselling with nutritional counselling plus placebo for 8 weeks. These last two trials were only considered in comparison three.</P>
<P>In general, adequate description of psychotherapy was provided. Number of individual CBT sessions ranged from sixteen to twenty-two, over a period of sixteen to twenty-four weeks. Four trials were conducted in the United States of America (<LINK REF="STD-Mitchell-1990" TYPE="STUDY">Mitchell 1990</LINK>, <LINK REF="STD-Agras-1992" TYPE="STUDY">Agras 1992</LINK>, <LINK REF="STD-Leitenberg-1994" TYPE="STUDY">Leitenberg 1994</LINK>, <LINK REF="STD-Walsh-1997" TYPE="STUDY">Walsh 1997</LINK>) one in Canada (<LINK REF="STD-Goldbloom-1996" TYPE="STUDY">Goldbloom 1996</LINK>), one in Germany (<LINK REF="STD-Fichter-1991" TYPE="STUDY">Fichter 1991</LINK>) and one in Australia (<LINK REF="STD-Russell-1995-b" TYPE="STUDY">Russell 1995 b</LINK>). All but the German study recruited outpatients from eating disorders programs and from the community, through advertisements. This study included patients who were undergoing intensive inpatient behavioral psychotherapy, in addition to pharmacotherapy or placebo. Six trials used DSM-III-R criteria for bulimia nervosa, and only one (<LINK REF="STD-Mitchell-1990" TYPE="STUDY">Mitchell 1990</LINK>) included bulimic patients diagnosed according to the DSM-III criteria. All patients were purging-type bulimic subjects, according to the DSM-IV definition ("regularly engaged in self-induced vomiting or misused laxatives, diuretics or enemas"). The study populations presented reasonably comparable demographic and behavioral features. They were mostly adult and young adult females; few adolescents were included. The mean number of bulimic episodes per week at baseline ranged roughly from 6 to 9. Patients with comorbid severe major depression, obesity, or substance abuse were usually not included in these studies.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>All included trials reported the randomisation procedure without adequate information on allocation concealment. Two studies (<LINK REF="STD-Leitenberg-1994" TYPE="STUDY">Leitenberg 1994</LINK>, <LINK REF="STD-Fichter-1991" TYPE="STUDY">Fichter 1991</LINK>) were classified as "A" according to the methodological quality assessment criteria, thanks to information provided by the authors. The other 5 trials were classified as "B". Agreement between authors for methodological quality grading was 100%. One trial (<LINK REF="STD-Russell-1995-b" TYPE="STUDY">Russell 1995 b</LINK>) excluded patients who dropped-out after randomisation from analysis and did not report an intention-to-treat analysis. Data was analysed on an intention-to-treat basis with dropouts being considered as not improved. </P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>Meta-analysis 1 (single antidepressants versus psychological treatments)</P>
<P>Remission<BR/>CBT was the psychological approach used in the five studies included in this comparison. Remission was reported in all trials. Overall remission rates were 20% for antidepressants and 39% for psychotherapy. Three individual studies showed no significant difference between antidepressants and individual CBT (<LINK REF="STD-Agras-1992" TYPE="STUDY">Agras 1992</LINK>, <LINK REF="STD-Goldbloom-1996" TYPE="STUDY">Goldbloom 1996</LINK>, <LINK REF="STD-Walsh-1997" TYPE="STUDY">Walsh 1997</LINK>). Two trials (<LINK REF="STD-Mitchell-1990" TYPE="STUDY">Mitchell 1990</LINK>, <LINK REF="STD-Leitenberg-1994" TYPE="STUDY">Leitenberg 1994</LINK>) showed a statistically significant difference favoring psychotherapy. When the more conservative DerSimonian-Laird estimate of pooled RR was used (random effects model), a clinically relevant but not statistically significant difference favouring psychological treatments was found (DL RR = 1.26; 95% CI= 0.90-1.78).</P>
<P>Clinical Improvement<BR/>This outcome was reported in only one trial. Therefore, it will not be considered in this review. </P>
<P>Dropouts<BR/>Four trials reported the number of dropouts per treatment group (<LINK REF="STD-Mitchell-1990" TYPE="STUDY">Mitchell 1990</LINK>, <LINK REF="STD-Agras-1992" TYPE="STUDY">Agras 1992</LINK>, <LINK REF="STD-Leitenberg-1994" TYPE="STUDY">Leitenberg 1994</LINK>, <LINK REF="STD-Goldbloom-1996" TYPE="STUDY">Goldbloom 1996</LINK>). Overall dropout rates for these short-term trials were higher for antidepressants than for psychotherapy (DL RR= 2.18; 95% CI= 1.09-4.35). Considering dropout rates of 40% for antidepressants and 18% for CBT, the NNH for a mean treatment duration of 17.5 weeks (min-max=10-24) was 4 (95% CI = 3-11). </P>
<P>Difference in bulimic symptoms<BR/>The analysis of the mean difference in bulimic symptoms was based on the number of patients who reported the number of bulimic episodes at the end of the trial. No difference was found between treatment groups in mean rates of bulimic episodes at baseline. The chi-square test suggested heterogeneity in the results of the studies. SMD was not significant either including or excluding the outlier study (<LINK REF="STD-Leitenberg-1994" TYPE="STUDY">Leitenberg 1994</LINK>).</P>
<P>Difference in depression<BR/>The analysis of the mean difference in depressive symptoms was also based on the number of patients who reported depression scores at the end of the trial. Three trials reported mean and standard deviations for depressive symptoms at endpoint (<LINK REF="STD-Leitenberg-1994" TYPE="STUDY">Leitenberg 1994</LINK>, <LINK REF="STD-Goldbloom-1996" TYPE="STUDY">Goldbloom 1996</LINK>, <LINK REF="STD-Walsh-1997" TYPE="STUDY">Walsh 1997</LINK>) and <LINK REF="STD-Goldbloom-1996" TYPE="STUDY">Goldbloom 1996</LINK> provided intention to treat data. Most trials did not include depressive patients and baseline mean depression scores were low. No difference between the two treatments was demonstrated. It was not possible to evaluate if the effects of antidepressants on bulimic symptoms were independent of their effect on depressive symptoms because individual patient data was not obtained.</P>
<P>Meta-analysis 2 (antidepressants versus combinations)</P>
<P>Remission<BR/>Remission was reported in four trials (Agras 1994, <LINK REF="STD-Leitenberg-1994" TYPE="STUDY">Leitenberg 1994</LINK>, <LINK REF="STD-Goldbloom-1996" TYPE="STUDY">Goldbloom 1996</LINK>, <LINK REF="STD-Walsh-1997" TYPE="STUDY">Walsh 1997</LINK>). In general, short-term remission of binge episodes was more likely in the combination than the single antidepressants group (42% versus 23%). DL RR for the four studies reporting this outcome was 1.40 (95% CI = 0.98-1.99) . The NNT for a mean treatment duration of 19 weeks (min-max=16-24), considering the non-remission rate in the antidepressants group of 77% as a measure of the baseline risk, was 5 (95% CI = 3 to 26). </P>
<P>Clinical improvement<BR/>As clinical improvement was reported in only one trial, this outcome was not analysed.</P>
<P>Dropouts<BR/>Overall dropout rates were high. Forty-one percent of the patients receiving single antidepressant treatment dropped out from the studies, compared to 34% of those randomised to the combined treatment (RR= 1.19; 95% CI 0.69-2.05). </P>
<P>Difference in bulimic symptoms<BR/>Four trials were included in the analysis (<LINK REF="STD-Leitenberg-1994" TYPE="STUDY">Leitenberg 1994</LINK>, <LINK REF="STD-Goldbloom-1996" TYPE="STUDY">Goldbloom 1996</LINK>, Agras 1994, <LINK REF="STD-Walsh-1997" TYPE="STUDY">Walsh 1997</LINK>). SMD was 0.34 (95% CI= -0.05-0.73) in favour, but just missing significance, of the combined treatment.</P>
<P>Difference in Depression<BR/>Three trials reported mean and standard deviations for depressive symptoms at endpoint (<LINK REF="STD-Walsh-1997" TYPE="STUDY">Walsh 1997</LINK>, <LINK REF="STD-Goldbloom-1996" TYPE="STUDY">Goldbloom 1996</LINK>, <LINK REF="STD-Leitenberg-1994" TYPE="STUDY">Leitenberg 1994</LINK>). SMD was 0.24 (95% CI = -0.14-0.62). As individual patient data was not available it was not possible to evaluate if the effects of antidepressants on bulimic symptoms were independent of their effect on depressive symptoms.</P>
<P>Meta-analysis 3 (psychological treatments versus combination)</P>
<P>Remission<BR/>Remission was reported in six trials (<LINK REF="STD-Leitenberg-1994" TYPE="STUDY">Leitenberg 1994</LINK>, <LINK REF="STD-Agras-1992" TYPE="STUDY">Agras 1992</LINK> , <LINK REF="STD-Russell-1995-b" TYPE="STUDY">Russell 1995 b</LINK>, <LINK REF="STD-Fichter-1991" TYPE="STUDY">Fichter 1991</LINK>, <LINK REF="STD-Goldbloom-1996" TYPE="STUDY">Goldbloom 1996</LINK>, <LINK REF="STD-Walsh-1997" TYPE="STUDY">Walsh 1997</LINK>). In general, short-term remission of binge episodes was more likely on the combination than the single psychological treatments group (49% versus 36%). DL RR was 1.21 (95% CI = 1.02-1.45). The NNT for a mean treatment duration of 15 weeks (min-max=5-24), considering the non-remission rate in the single psychological treatments group of 64% as a measure of the baseline risk, was 8 (95% CI = 4 - 320). Similar results were obtained when nutritional counselling was removed from the analysis (RR = 1.20; 95% CI 1.00-1.44). The RR for the CBT trials was 1.23 (95% CI 0.95-1.60). </P>
<P>Clinical improvement<BR/>Clinical improvement could be obtained from two trials (<LINK REF="STD-Fichter-1991" TYPE="STUDY">Fichter 1991</LINK>, <LINK REF="STD-Leitenberg-1994" TYPE="STUDY">Leitenberg 1994</LINK>). No difference between treatments could be shown (RR= 0.90; 95% CI = 0.30-2.66).</P>
<P>Dropouts<BR/>A statistical significant difference in acceptability of treatment was shown. Dropout rates were 16% for the single psychological treatments and 30% for the combined treatment groups (RR= 0.57; 95% CI = 0.38 - 0.88). The NNH for a mean treatment duration of 14 weeks (min-max=10-24) was 7 (95 % CI = 4 - 21). </P>
<P>Difference in bulimic symptoms<BR/>SMD for difference in bulimic symptoms was 0.12 (95% CI= -0.21 - 0.46). </P>
<P>Difference in depression<BR/>The analysis of mean difference in depressive symptoms included 5 trials (<LINK REF="STD-Russell-1995-b" TYPE="STUDY">Russell 1995 b</LINK>, <LINK REF="STD-Fichter-1991" TYPE="STUDY">Fichter 1991</LINK>, <LINK REF="STD-Goldbloom-1996" TYPE="STUDY">Goldbloom 1996</LINK>, <LINK REF="STD-Leitenberg-1994" TYPE="STUDY">Leitenberg 1994</LINK>, <LINK REF="STD-Walsh-1997" TYPE="STUDY">Walsh 1997</LINK>). SMD was 0.13(95% CI= -0.27 - 0.53). </P>
<P>Remission and dropout rates were similar for both "single" psychotherapy treatment groups: the one receiving psychological treatment combined to medication placebo and the one receiving psychological treatments without medication placebo (38% versus 33% for remission and 14% versus 18.5% for dropouts). So, results favouring effectiveness of combination of psychological treatments with active antidepressant medications and acceptability of single psychological treatments can not be interpreted as a result of a reduced effectiveness of psychological treatments due to the combined use of medication placebo.<BR/>For meta-analysis 1, the fail-safe N for the outcome "dropouts" was 8. This is the number of studies (with null results) needed to overturn the results of the combined significant test. In meta-analysis 2, the fail-safe N for the outcome "remission" was 0; in meta-analysis 3, the fail-safe N for the outcome "remission" was 0 and for the outcome "dropouts" it was 3.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Most guidelines for treatment of bulimia nervosa report that psychotherapy in general, and CBT in particular, is the "gold standard" therapeutic approach (<LINK REF="REF-Fairburn-1991" TYPE="REFERENCE">Fairburn 1991</LINK>). Medication is frequently proposed as a supplement to education, nutritional rehabilitation and psychotherapy. CBT alone is generally considered superior to antidepressants alone. Reasons for not using medication as the exclusive treatment of bulimia nervosa usually include: the overall effectiveness of well-established psychological interventions is considered to be good; CBT seems more acceptable to patients than antidepressant medication as the dropout rates are higher with the latter; longer term maintenance of change appears to be better with CBT than antidepressant drugs, as relapse rates with drug discontinuation seem to be high. Nonetheless, CBT is under-utilized, mainly due to the relative unavailability of therapists with specialized training in CBT for eating disorders in many countries. Combining psychological treatments with antidepressant drugs is usually considered more effective than using drugs alone, but to produce few consistent benefits over CBT alone.</P>
<P>This review demonstrates the small number of available trials on direct comparisons between medications and psychotherapy or comparing the combination of antidepressants and psychological treatments with each single approach to guide clinical decisions for the treatment of bulimia nervosa. All studies identified by the search strategy were published in the last decade, showing the increasing interest in evaluating combination strategies to improve efficacy and acceptability of treatments for bulimia nervosa.</P>
<P>Four out of seven trials included in this review used classical individual CBT. One trial used an intensive group CBT. Intensive inpatient psychotherapy and nutritional counselling were used in the remaining studies. It could be argued that combining such different treatments is not sensible. However, in this review no difference among these treatments could be shown, as indicated by the sensitivity analysis. Considering the small number of trials, with rather reduced sample sizes, a more conservative statistical approach seemed more appropriate. </P>
<P>All participants were patients with purging type bulimia nervosa. Those with severe comorbid depression, obesity and substance abuse were usually excluded from the trials. Patients were recruited through advertising in the majority of studies. These patients may differ on some demographic, clinical and psychological variables from nonrecruited bulimic patients. It was not possible in this review to determine whether the source of referral influenced treatment outcome. Therefore there may be limitations on the generalisability of the findings from this review. </P>
<P>Remission rates for single antidepressants were equivalent to those found in another meta-analysis comparing different classes of antidepressants with placebo (<LINK REF="REF-Bacaltchuk-2000-a" TYPE="REFERENCE">Bacaltchuk 2000 a</LINK>). About 20% of the patients were "free" of binge-eating episodes at the end of the short-term trials. Figures were better in the single psychotherapy group, but still not very high (less than 40%). It is possible that the statistical power was insufficient to demonstrate a significant difference in efficacy between the two single approaches. This difference seems, however, clinically relevant. When psychological treatments were combined with antidepressants, efficacy of each single approach was improved. This better outcome may be related to a host of possible factors, including patients and therapists preferences. The increased efficacy of the combined treatments was statistically significant when compared to single psychological treatments and marginally significant but clinically relevant when compared to single antidepressants. Nevertheless, some authors are more cautious about the added value of the combined therapy on the cardinal features of binge eating or purging behaviours in BN (<LINK REF="STD-Mitchell-1990" TYPE="STUDY">Mitchell 1990</LINK>, <LINK REF="STD-Agras-1992" TYPE="STUDY">Agras 1992</LINK>). It must be pointed out that as only one trial reported remission rates for SSRIs, conclusions are necessarily limited with respect to clinical guidance regarding choice of drug.</P>
<P>Data from these seven trials confirmed that single psychological treatments are a better-accepted therapeutic approach. Many patients with BN appear reluctant to take antidepressant medications and even reject participate in trials with madication-only treatment groups (<LINK REF="STD-Leitenberg-1994" TYPE="STUDY">Leitenberg 1994</LINK>) prefering psychological approaches. The combination of antidepressants with psychological treatments were less accepted than psychological treatments alone. </P>
<P>Only two of these seven comparative studies have reported longer term follow-up (<LINK REF="STD-Mitchell-1987-b" TYPE="STUDY">Mitchell 1987 b</LINK>, <LINK REF="STD-Agras-1992" TYPE="STUDY">Agras 1992</LINK>). Both suggest a better maintenance of change with CBT.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>The current findings are based on a small number of trials, most of them including few patients. According to the fail-safe N calculations, results are not strong and more trials are necessary to confirm these findings. One single trial with null results could overturn the significant results regarding efficacy. For that reason, clinical recommendations at this point in time must be cautious. Another important issue in clinical practice is the effect variation according to dose and compliance. The limited discussion in this review regarding medications dose and assessment of compliance, among other relevant questions, is determined by restricted information available in original studies and the limitations of meta-analysis itself. Such statistical summary can not answer important questions if the original RCTs were not designed for that purpose. As long as new studies are not available, combination of antidepressants and psychological treatments may be recommended as an efficient treatment for bulimia nervosa, particularly when bulimic symptoms are very severe and a single approach has been only partially successful. In many clinical settings where a psychotherapist trained for the treatment of eating disorders is available, single CBT is frequently indicated as a first therapeutic choice. Antidepressant medications may be considered a first-line treatment if a skilled psychotherapist is not available. If an increased efficacy of single CBT is needed, augmentation with antidepressants can be recommended. When adding antidepressants it may be sensible to implement measures to prevent dropouts.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>More studies with higher sample sizes are needed in order to better estimate the differential effectiveness and acceptability of these two therapeutic approaches. Well-designed and unbiased RCTs evaluating short and long-term outcomes, including relapse and maintenance of remission, are necessary. It is also important to better define which is the most adequate outcome to be evaluated and examine predictors of response to each treatment and the effects of combined treatments (psychotherapy plus medication). Meanwhile, trials should systematically report remission rates, the number of patients that do not fulfill diagnostic criteria at the end of the trial, as well as other relevant dimensions of response.</P>
<P>Other psychological interventions, such as interpersonal, psychodynamic, supportive-expressive and focal interpersonal psychotherapies, self-help and behavioral treatments, should also be compared to antidepressants and combined treatments. Further evaluation is needed of longer-term medication trials and of other drug therapies, such as the new antiepileptics, as well as of two stage interventions.</P>
<P>New trials should also include bulimic patients with severe comorbid conditions frequently seen in clinical settings (like depression and substance abuse), as well as adolescent patients. Raters should always be blind to treatments and patients and investigators should systematically be questioned about treatment preferences in order to detect possible bias. A question raised by this data is whether CBT is cost-effective when compared to antidepressants in a short-term. Specifically designed studies allowing for economic analysis should be performed to clarify this point.</P>
<P>It is of note that since the inception of this review (first search dated to 1997) there have been no new trials in this area. As with the research in the area of antidepressant treatment efficacy for bulimia nervosa, there are likely several reasons for this. They include the possible greater acceptance of psychotherapy by clinicians and patients, and the costs of further trials for the use of medication in areas other than that of their first indication. However, the hypothesis that combined approaches improve the acceptability of antidepressants, and appear to be more efficacious than either approach alone, needs to be confirmed.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>Professors Jair J Mari (Federal University of Sao Paulo) and Irismar R de Oliveira (Fedral University of Bahia), and Roberta P Trefiglio, who provided invaluable advice and support; Hugh McGuire and the Cochrane Collaboration Depression, Anxiety and Neuroses Group who provided the access to the CCDAN database and advice and support and the search updates. All the authors who provided trial information, some many years after the studies were competed. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None. </P>
<P>JB has received fees from Janssen-Cilag Farmaceutica, Brazil. PH has received supprot to attend conferences and meetings from Pfizer PTY Ltd, Solvay Pharmaceuticals and Bristol-Myers Squibb Pharmaceuticals.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS/>
<PRO_REV_DIFF/>
<PUBLIC_NOTES>
<P>This review is in the process of being updated. We hope to publish the updated version in Issue 2, 2008.<BR/>
</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-02-25 12:13:13 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2010-02-25 12:13:13 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Agras-1992" NAME="Agras 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Agras WS, Rossiter EM, Arnow B, Schneider JA, Telch CF, Raeburn SD et al</AU>
<TI>Pharmacologic and cognitive-behavioral treatment for bulimia nervosa: a controlled comparison</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1992</YR>
<VL>149</VL>
<NO>1</NO>
<PG>82-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Fichter-1991-a" NAME="Fichter 1991 a" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fichter MM, Leibl K, Rief W, Brunner E, Schmidt-Auberger S, Engel RR</AU>
<TI>Fluoxetine versus placebo: a double blind study with bulimic inpatients udergoing intensive psychotherapy</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1991</YR>
<VL>24</VL>
<PG>1-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Goldbloom-1996" NAME="Goldbloom 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Author supplied unpublished data as well&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Goldbloom DS, Olmsted MP, Davies R, Shaw B</AU>
<TI>A randomized control trial of fluoxetine and cognitive behavioural therapy for bulimia nervosa: short-term outcome</TI>
<SO>Behavioral Research and Therapy</SO>
<YR>1997</YR>
<VL>35</VL>
<NO>9</NO>
<PG>803-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Leitenberg-1994" NAME="Leitenberg 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Leitenberg H, Rosen JC, Wolf J, Vara LS, Detzer MJ, Srebnik D</AU>
<TI>Comparison of cognitive-behavior therapy and desipramine in the treatment of bulimia nervosa</TI>
<SO>Behavioral Research and Therapy</SO>
<YR>1994</YR>
<VL>32</VL>
<NO>1</NO>
<PG>37-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mitchell-1990" NAME="Mitchell 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mitchell JE, Pyle RL, Eckert ED, Hatsukami D, Pomeroy C, Zimmerman R</AU>
<TI>A comparison study of antidepressants and structured intensive group psychoterapy in the treatment of bulimia nervosa</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1990</YR>
<VL>47</VL>
<NO>2</NO>
<PG>149-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Russell-1995-b" NAME="Russell 1995 b" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Beumont PJ, Russell JD, Touyz SW, Buckley C, Lowinger K, Talbot P et al</AU>
<TI>Intensive nutritional counselling in bulimia nervosa: a role for supplementation with fluoxetine?</TI>
<SO>Australian and New Zealand Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>31</VL>
<NO>4</NO>
<PG>514-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Walsh-1997" NAME="Walsh 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Walsh BT, Wilson GT, Loeb KL, Devlin MJ, Pike KM, Roose SP, Fleiss J, Waternaux C</AU>
<TI>Medication and psychotherapy in the treatment of bulimia nervosa</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>154</VL>
<NO>4</NO>
<PG>523-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-02-25 12:13:13 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Agras-1987" NAME="Agras 1987" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Agras WS, Dorian B, Kirkley BG, Arnow B, Bachman J</AU>
<TI>Imipramine in the treatment of bulimia: a double -blind controlled study</TI>
<SO>International Journal of Eating Disorders</SO>
<YR>1987</YR>
<VL>6</VL>
<PG>29-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alger-1991" NAME="Alger 1991" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Alger AS, Shwalberg MD, Bigaouette JM, Michalek AV, Howard LJ.</AU>
<TI>Effect of a tricyclic antidepressant and opiate antagonist on binge-eating behavior in normoweight bulimic and obese, binge-eating subjects</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1991</YR>
<VL>53</VL>
<NO>4</NO>
<PG>865-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barlow-1988" MODIFIED="2010-02-25 12:13:13 +0000" MODIFIED_BY="[Empty name]" NAME="Barlow 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-02-25 12:13:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Barlow J, Blouin J, Blouin A, Perez E</AU>
<TI>Treatment of bulimia with desipramine: a double-blind crossover study</TI>
<SO>Canadian Journal of Psychiatry</SO>
<YR>1988</YR>
<VL>33</VL>
<NO>2</NO>
<PG>129-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blouin-1988" NAME="Blouin 1988" YEAR="1988">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Blouin AG, Blouin JH, Perez EL, Bushnik T, Zuro C, Mulder E.</AU>
<TI>Treatment of bulimia with fenfluramine and desipramine</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1988</YR>
<VL>8</VL>
<NO>4</NO>
<PG>261-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Box-1983" NAME="Box 1983" YEAR="1983">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Box J, Arnold E, Smeltzer DJ</AU>
<TI>Protriptyline weight loss in compulsive eaters: a placebo-controlled study</TI>
<SO>Journal of Psychiatric Treatment and Evaluation</SO>
<YR>1983</YR>
<VL>5</VL>
<NO>4</NO>
<PG>387-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-FBNCSG-1992" NAME="FBNCSG 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fluoxeting Bulimia Nervosa Collaborative Study Group</AU>
<TI>Fluoxetine in the treatment of bulimia nervosa</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1992</YR>
<VL>49</VL>
<NO>2</NO>
<PG>139-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fichter-1991" NAME="Fichter 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fichter MM, Krüger R, Rief W, Holland R, Döhne J</AU>
<TI>Fluvoxamine in prevention of relapse in bulimia nervosa: effects on eating specific psychopathology</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1996</YR>
<VL>16</VL>
<PG>9-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fichter MM, Leibl K, Rief W, Brunner E, Schmidt-Auberger S, Engel RR</AU>
<TI>Fluoxetine versus placebo: a double blind study with bulimic inpatients udergoing intensive psychotherapy.</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1991</YR>
<VL>24</VL>
<PG>1-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horne-1988" NAME="Horne 1988" YEAR="1988">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Horne RL, Ferguson JM, Pope HG Jr, Hudson JI, Lineberry CG, Ascher J et al</AU>
<TI>Treatment of bulimia with bupropion: a multicenter controlled trial</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1988</YR>
<VL>49</VL>
<NO>7</NO>
<PG>262-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hughes-1986-a" NAME="Hughes 1986 a" YEAR="1986">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hughes PL, Wells LA, Cunningham CJ, Ilstrup DM</AU>
<TI>Treating bulimia with desipramine. A double-blind, placebo-controlled study</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1986</YR>
<VL>43</VL>
<NO>2</NO>
<PG>182-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kanerva-1994" NAME="Kanerva 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kanerva R, Rissanen A, Sarna S</AU>
<TI>Fluoxetine in the treatment of anxiety, depressive symptoms, and eating-related symptoms in bulimia nervosa</TI>
<SO>Nordic Journal of Psychiatry</SO>
<YR>1994</YR>
<VL>49</VL>
<NO>4</NO>
<PG>237-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kennedy-1986" NAME="Kennedy 1986" YEAR="1986">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kennedy S, Piran N, Garfinkel PE</AU>
<TI>Isocarboxazide in the treatment of bulimia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1986</YR>
<VL>143</VL>
<NO>11</NO>
<PG>1495-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kennedy-1988" NAME="Kennedy 1988" YEAR="1988">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kennedy SH, Piran N, Warsh JJ, Prendergast P, Mainprize E, Whynot C et al</AU>
<TI>A trial of isocarboxazid in the treatment of bulimia nervosa</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1988</YR>
<VL>8</VL>
<NO>6</NO>
<PG>391-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kennedy-1993" NAME="Kennedy 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kennedy SH, Goldbloom DS, Ralevski E, Davis C, D&#8217;Souza JD, Lofchy JE</AU>
<TI>Is there a role for selective monoamine oxidase inhibitor therapy in bulimia nervosa? A placebo-controlled trial of braforamin</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1993</YR>
<VL>13</VL>
<NO>6</NO>
<PG>415-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marcus-1990" NAME="Marcus 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Marcus MD, Wing RR, Ewing L, Kern E, McDermott M, Gooding W</AU>
<TI>A double-blind placebo-controlled trial of fluoxetine plus behavioral modification in the treatment of obese binge-eaters</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1990</YR>
<VL>147</VL>
<NO>7</NO>
<PG>876-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Margittai-1987" NAME="Margittai 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Subset of Barlow 1988&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Margittai KJ, Blouin A, Perez E</AU>
<TI>A study of dropouts in psychopharmacological research with bulimics</TI>
<SO>International Journal of Psychiatry in Medicine</SO>
<YR>1987</YR>
<VL>16</VL>
<NO>4</NO>
<PG>297-304</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCann-1990" NAME="McCann 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McCann UD, Agras WS</AU>
<TI>Successful treatment of nonpurging bulimia nervosa with desipramine: a double-blind, placebo-controlled study</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1990</YR>
<VL>147</VL>
<NO>11</NO>
<PG>1509-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mitchell-1984" NAME="Mitchell 1984" YEAR="1984">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mitchell JE, Groat R</AU>
<TI>A placebo-controlled double-blind trial of amitriptyline in bulimia.</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1984</YR>
<VL>4</VL>
<NO>4</NO>
<PG>186-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mitchell-1987-b" NAME="Mitchell 1987 b" YEAR="1987">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pyle RL, Mitchell JE, Eckert ED, Hatsukami D, Pomeroy C, Zimmerman R</AU>
<TI>Maintenance treatment and 6-month outcome for bulimic patients who respond to initial treatment</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1990</YR>
<VL>147</VL>
<NO>7</NO>
<PG>871-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pope-1983" NAME="Pope 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Two year follow-up of Pope 1983&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pope HG, Hudson JI Jonas JM, Yurgelun-Todd D.</AU>
<TI>Antidepressant treatment of bulimia: a two-year follow-up study</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1985</YR>
<VL>5</VL>
<NO>6</NO>
<PG>320-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pope HG, Hudson JI, Jonas JM, Yurgelum-Todd D.</AU>
<TI>Bulimia treated with imipramine</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1983</YR>
<VL>140</VL>
<NO>5</NO>
<PG>554-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pope-1989" NAME="Pope 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pope HG, Keck PE, McElroy S, Hudson JI</AU>
<TI>A placebo-controlled study of trazodone in bulimia nervosa</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1989</YR>
<VL>9</VL>
<NO>4</NO>
<PG>254-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Price-1987" NAME="Price 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Price W, Massood RB, Youngstrom O</AU>
<TI>Antidepressant drug therapy for bulimia: Current status revisited</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1987</YR>
<VL>48</VL>
<NO>9</NO>
<PG>385</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rothschild-1994" NAME="Rothschild 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rothschild R, Quitkin HM, Quiktin FM, Stewart JW, Ocepek-Welikson K, McGrath PJ, Tricamo E</AU>
<TI>A double-blind placebo-controlled comparison of phenelzine and imipramine in the treatment of bulimia in atypical depressives</TI>
<SO>International Journal of Eating Disorders</SO>
<YR>1994</YR>
<VL>15</VL>
<PG>1-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sabine-1983" NAME="Sabine 1983" YEAR="1983">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sabine EJ, Yonace A, Farrington AJ, Barrant KH, Wakeling A</AU>
<TI>Bulimia nervosa: a placebo-controlled double-blind therapeutic trial of mianserin</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1983</YR>
<VL>15</VL>
<NO>Suppl 2</NO>
<PG>195-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scrimali-1994" NAME="Scrimali 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Scrimali T, Grimali L, Corriere A, Grasso F, Frisone MF</AU>
<TI>Fluoxetine in the pharmacological treatment of bulimia nervosa</TI>
<TO>La fluoxetina nel tratamento farmacologico della bulimia nervosa</TO>
<SO>Rivista di Psichiatria</SO>
<YR>1994</YR>
<VL>29</VL>
<NO>3</NO>
<PG>171-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Walsh-1984" NAME="Walsh 1984" YEAR="1984">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Walsh T, Stewart JW, Roose, Gladis M, Glassman AH</AU>
<TI>Treatment of bulimia with phenelzine</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1984</YR>
<VL>41</VL>
<NO>11</NO>
<PG>1105-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Walsh-1985" NAME="Walsh 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Walsh BT, Stewart JW, Roose SP, Gladis M, Glassman AH</AU>
<TI>A double-blind trial of phenelzine in bulimia</TI>
<SO>Journal of Psychiatric Research</SO>
<YR>1985</YR>
<VL>19</VL>
<NO>2-3</NO>
<PG>485-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Walsh-1991-a" NAME="Walsh 1991 a" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Walsh BT, Hadigan CM, Devlin MJ, Gladis M, Roose SP</AU>
<TI>Long-term outcome of antidepressant treatment for bulimia nervosa.</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1991</YR>
<VL>148</VL>
<NO>9</NO>
<PG>1206-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Walsh T, Hadigan CM, Wong LM</AU>
<TI>Increased pulse and blood pressure associated with desipramine treatment of bulimia nervosa</TI>
<SO>Journal of Clinical Psychopharamacology</SO>
<YR>1992</YR>
<VL>12</VL>
<NO>3</NO>
<PG>163-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wheadon-1992" NAME="Wheadon 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Goldstein DJ, Wilson MG, Thomson VL, Potvin JH, Rampey AH Jr</AU>
<TI>Long-term fluoxetine treatment of bulimia nervosa</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1995</YR>
<VL>166</VL>
<PG>660-666</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Advokat-1995" NAME="Advokat 1995" TYPE="JOURNAL_ARTICLE">
<AU>Advokat C, Kutlesic V</AU>
<TI>Pharmacotherapy of the eating disorders: a commentary</TI>
<SO>Neuroscience and Biobehavioral Reviews</SO>
<YR>1995</YR>
<VL>19</VL>
<NO>1</NO>
<PG>59-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-1980" NAME="APA 1980" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and Statistical Manual of mental disorders (DSM-III)</SO>
<YR>1980</YR>
<EN>3rd</EN>
<PB>American Psychiatric Association</PB>
<CY>Washington DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-1987" NAME="APA 1987" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and Statistical Manual of mental disorders (DSM-III-R)</SO>
<YR>1987</YR>
<EN>3rd Revised</EN>
<PB>American Psychiatric Association</PB>
<CY>Washington DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-1994" NAME="APA 1994" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and Statistical Manual of mental disorders (DSM-IV)</SO>
<YR>1994</YR>
<EN>4th</EN>
<PB>American Psychiatric Association</PB>
<CY>Washington DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bacaltchuk-2000-a" NAME="Bacaltchuk 2000 a" TYPE="JOURNAL_ARTICLE">
<AU>Bacaltchuk J, Hay P, Mari JJ</AU>
<TI>Antidepressants versus placebo for the treatment of bulimia nervosa: a systematic review</TI>
<SO>Australian and New Zealand Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>34</VL>
<NO>2</NO>
<PG>310-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Buchan-1997" NAME="Buchan 1997" TYPE="BOOK">
<AU>Buchan IE</AU>
<SO>Arcus QuickStat Biomedical for windows</SO>
<YR>1997</YR>
<EN>1</EN>
<PB>Addison Wesley Longman Limited trading as Research Solutions</PB>
<CY>Cambridge UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen-1988" NAME="Cohen 1988" TYPE="BOOK">
<AU>Cohen J</AU>
<SO>Statistical Power for the Behavioral Sciences</SO>
<YR>1988</YR>
<EN>2nd</EN>
<PB>Lawrence Erlbaum</PB>
<CY>Hillsdale NJ</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cook-1995" NAME="Cook 1995" TYPE="JOURNAL_ARTICLE">
<AU>Cook RJ, Sackett DL</AU>
<TI>The number needed to treat: a clinically useful measure of treatment effect</TI>
<SO>BMJ</SO>
<YR>1995</YR>
<VL>310</VL>
<NO>6977</NO>
<PG>452-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Corcos-1996" NAME="Corcos 1996" TYPE="JOURNAL_ARTICLE">
<AU>Corcos M, Flament M, Atger F, Jeammet PH</AU>
<TI>Pharmacological treatment of bulimia</TI>
<TO>Traitement pharmacologique de la bulimie</TO>
<SO>Encephale</SO>
<YR>1996</YR>
<VL>22</VL>
<NO>2</NO>
<PG>133-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cucherat-1997" NAME="Cucherat 1997" TYPE="BOOK">
<AU>Cucherat M</AU>
<SO>Meta-analyse des essais therapeutiques</SO>
<YR>1997</YR>
<PB>Masson</PB>
<CY>Paris</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1996" NAME="DerSimonian 1996" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fairburn-1991" NAME="Fairburn 1991" TYPE="BOOK_SECTION">
<AU>Fairburn CG, Marcus MD, Wilson GT</AU>
<TI>Cognitive behavioural therapy for treatment of bulimia nervosa</TI>
<SO>Binge eating: Nature, assessment and treatment</SO>
<YR>1993</YR>
<PG>361-404</PG>
<ED>Fairburn CG, Wilson GT</ED>
<PB>Guilford Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Foreyt-1996" NAME="Foreyt 1996" TYPE="JOURNAL_ARTICLE">
<AU>Foreyt JP, Poston WS, Goodrick GK</AU>
<TI>Future directions in obesity and eating disorders</TI>
<SO>Addictive Behaviours</SO>
<YR>1996</YR>
<VL>21</VL>
<NO>6</NO>
<PG>767-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hay-2000" NAME="Hay 2000" TYPE="COCHRANE_REVIEW">
<AU>Hay PJ, Bacaltchuk J</AU>
<TI>Psychotherapy for bulimia nervosa and binge eating</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>4</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hedges-1985" NAME="Hedges 1985" TYPE="BOOK">
<AU>Hedges LV, Olkin I</AU>
<SO>Statistical methods for meta-analysis</SO>
<YR>1985</YR>
<PB>Academic Press</PB>
<CY>San Diego CA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad A, Moore A, Carrol D, Jenkinson C, Reynolds DJ, Gavanagh DJ et al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: Is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Light-1984" NAME="Light 1984" TYPE="BOOK">
<AU>Light RJ, Pillemer DB</AU>
<SO>Summing up: The Science of Revieweing Research</SO>
<YR>1984</YR>
<PB>Harvard University Press</PB>
<CY>Cambridge MA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lima-1998" NAME="Lima 1998" TYPE="COCHRANE_REVIEW">
<AU>Lima MS, Montcrieff J</AU>
<TI>A comparison of drugs versus placebo for the treatment of dysthymia: a systematic review</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1998</YR>
<NO>2</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mitchell-1991" NAME="Mitchell 1991" TYPE="JOURNAL_ARTICLE">
<AU>Mitchell JE, Specker SM, de Zwaan M</AU>
<TI>Comorbidity and medical complications of bulimia nervosa</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1991</YR>
<VL>52</VL>
<NO>Suppl</NO>
<PG>13-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mulrow-1996" NAME="Mulrow 1996" TYPE="BOOK">
<AU>Mulrow CD, Oxman AD</AU>
<SO>Cochrane Collaboration Handbook</SO>
<YR>1996</YR>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosenthal-1979" NAME="Rosenthal 1979" TYPE="JOURNAL_ARTICLE">
<AU>Rosenthal R</AU>
<TI>The "file drawer problem" and the tolerance for null results</TI>
<SO>Psychological Bulletin</SO>
<YR>1979</YR>
<VL>86</VL>
<NO>3</NO>
<PG>638-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Russell-1979" NAME="Russell 1979" TYPE="JOURNAL_ARTICLE">
<AU>Russell GF</AU>
<TI>Bulimia nervosa: an ominous variant of anorexia nervosa</TI>
<SO>Psychological Medicine</SO>
<YR>1979</YR>
<VL>9</VL>
<NO>3</NO>
<PG>429-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sackett-1994" NAME="Sackett 1994" TYPE="BOOK">
<AU>Sackett DL</AU>
<SO>Cochrane Collaboration Handbook</SO>
<YR>1994</YR>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schultz-1995" NAME="Schultz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schultz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-412</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shaw-1990" NAME="Shaw 1990" TYPE="JOURNAL_ARTICLE">
<AU>Shaw B, Garfinkel PE</AU>
<TI>Research problems in the eating disorders</TI>
<SO>International Journal of Eating Disorders</SO>
<YR>1990</YR>
<VL>9</VL>
<NO>5</NO>
<PG>545-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thomson-1995" NAME="Thomson 1995" TYPE="BOOK_SECTION">
<AU>Thomson SG</AU>
<TI>Why sources of heterogeneity in meta-analysis should be investigated</TI>
<SO>Systematic Reviews</SO>
<YR>1995</YR>
<PG>48-63</PG>
<ED>Chalmers I, Altman DG</ED>
<PB>BMJ Publishing</PB>
<CY>Bristol</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walsh-1997-a" NAME="Walsh 1997 a" TYPE="JOURNAL_ARTICLE">
<AU>Walsh BT, Wilson GT, Loeb KL, Devlin MJ, Pike KM, Roose SP et al</AU>
<TI>Medication and psychotherapy in the treatment of bulimia nervosa</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>154</VL>
<NO>4</NO>
<PG>523-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1992" NAME="WHO 1992" TYPE="BOOK">
<AU>World Health Organisation</AU>
<SO>The ICD-10 Classification of Mental and Behavioral Disorders. Clinical Descriptions and diagnostic guidelines</SO>
<YR>1992</YR>
<PB>WHO</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilson-1995" NAME="Wilson 1995" TYPE="BOOK_SECTION">
<AU>Wilson GT</AU>
<TI>Empirically validated treatments as a basis for clinical practice. Problems and prospects</TI>
<SO>Scientific standards of psychological practice: Issues and recommendations</SO>
<YR>1995</YR>
<PG>163-96</PG>
<ED>Hayes SC, Follette VM, Risley T, Dawes RD, Grady K</ED>
<PB>Context Press</PB>
<CY>Reno NV</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wolfe-1995" NAME="Wolfe 1995" TYPE="JOURNAL_ARTICLE">
<AU>Wolfe BE</AU>
<TI>Dimensions of response to antidepressant in bulimia nervosa: a review</TI>
<SO>Archives of Psychiatric Nursing</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>3</NO>
<PG>111-21</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES>
<REFERENCE ID="REF-Bacaltchuk-1999" NAME="Bacaltchuk 1999" TYPE="JOURNAL_ARTICLE">
<AU>Bacaltchuk J, Trefiglio RP, Oliveira IR, Lima MS, Mari JJ</AU>
<TI>Antidepressants versus psychotherapy for bulimia nervosa: a systematic review</TI>
<SO>Journal of Clinical Pharmacy and Therapeutics</SO>
<YR>1999</YR>
<VL>24</VL>
<NO>1</NO>
<PG>23-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bacaltchuk-2000" NAME="Bacaltchuk 2000" TYPE="JOURNAL_ARTICLE">
<AU>Bacaltchuk J, Trefiglio RP, Oliveira IR, Hay P, Lima MS, Mari JJ</AU>
<TI>Combination of antidepressants and psychological treatments for bulimia nervosa: a systematic review</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>2000</YR>
<VL>101</VL>
<NO>4</NO>
<PG>256-64</PG>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-02-25 12:12:52 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Agras-1992">
<CHAR_METHODS>
<P>RCT, 24 weeks, ITT. Assessor blind to assignment, different from physicians</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>DSM-III-R BN; 18-65 years old, mean: 30 years old, recruited from eating disorder clinic + ads. Binges/w: 9,2. Purges/w: 7,5. Beguin BN: 20 years old</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Desipramine (15 min sessions): 25 mg/3days,, till 300 mg( 25-50 mg / 3-5 days. Mean: 167mg/day. versus CBT: 50 min sessions, experienced therapists (5 years)<BR/>-self monitoring eating behaviors<BR/>-3 or more meals per day<BR/>-cognitive restructuring<BR/>relapse prevention<BR/>Supervised ttt, 15 sessions/16 weeks, follow-up at weeks 20 and 24k</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Remission (at 32 weeks)<BR/>Change in bulimic symptoms<BR/>Drop-outs to any cause<BR/>Depr: BDI, not done</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Fichter-1991-a">
<CHAR_METHODS>
<P>RCT, sealed envelopes and identical capsules, 5 weeks duration</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>BN DSM-III-R, 39 female, 1 male.Age: 24.6(pl);26.5(fl). Onset of eating dis: 16 years old.Binges/w: 8.8(pl); 5.6(fl). HDRS: 14.1(pl]); 13.3(fl)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Fluoxetine 60mg versus placebo plus intensive inpatient psychotherapy (behavioral)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Remission<BR/>Clinical Improvement<BR/>Deterioration<BR/>Change in bulimic symptoms<BR/>Drop-outs to any cause<BR/>Depression (HDRS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Goldbloom-1996">
<CHAR_METHODS>
<P>RCT,16 weeks, not ITT, self assessments, follow-up 4 weeks after the end of the trial, experienced psychiatrists or psychologists, independent assessor</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>BN DSM-III-R, 6 month duration, 2 episodes per week, n= 76, referred by health professionals to Eating Disorders Program, females, Age= 18-45 years, mean of completers: 25.8, 85-125% population mean weight, BMI of completers:20</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Fluoxetine 60 mg versus CBT versus combination. CBT= Fairburn, 16 sessions over 16 weeks, 1 hr. sessions, FL= 10 sessions, 10 min.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Remission not ITT<BR/>Drop-outs due to any cause<BR/>Depression: Beck</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Author supplied unpublished data</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Leitenberg-1994">
<CHAR_METHODS>
<P>RCT, 20 weeks, self records(diaries)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>BN DSM-III-R + Russell, 4 episodes of vomiting/week/2weeks, women, 18-45 years old, mean 26.7, 80-120% normal weight, newspaper advertisement and referrals, duration=83.48 months, vomiting/week baseline=8.5<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Desipramine &gt;= 150 mg versus CBT versus combinations. 22 sessions of CBT, 20 weeks, 1 and 1/2 to 2 hours sessions. Fairburn CBT with exposure to eating feared foods plus response prevention (vomiting). DFesipramine alone group sessions: 15 min. Start dose:50 mg/d, increases of 50 mg every 3 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Remission<BR/>Clinical improvement<BR/>Change in bulimic symptoms<BR/>Drop-outs due to any cause</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>IDD is highly correlated to BDI</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Mitchell-1990">
<CHAR_METHODS>
<P>RCT, 10 weeks, physicians responsible for medication management were blind to randomization.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Bulimia DSM-III, 3 episodes/week/6 months, patients being evaluated in ED clinic and advertisements. Age 18-40, mean 24, female, 80-120% ideal body weight, mean 107%, duration of illness 6.5 years,binges/week baseline=7,3(i)/ 8,0(pl)/ 9,2(pt)/ 8.4(comb).HDRS baseline=11</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Imipramine versus Intensive CBT versus combinations. Initial dose 50 mg, increments to 200 mg for 2 weeks, maintained for 2 weeks, if necessary 300 mg.CBT= 3 phases. 1= 2 hour sessions for each week 2 weeks: mael planning and CBT techniques. 2=arttempt to interrupt bulimic behaviors begin eating regular meals, use of CBT techniques,5 nights a week, 3 hour sessions, then 2 sessions/week (lecture+diner+psychotherapy). 3= last month: 1 and half hour sessions, exposure and relapse prevention</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Drop-outs due to any cause</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>HDRS</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Russell-1995-b">
<CHAR_METHODS>
<P>RCT, parallel,DB, 8 weeks. Placebo wash out 7-10 days run in. ITT analysis. Patient diaries. Assessors different from therapists</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>DSM-III-R BN. Age: 24,2 (fl) 25,1(pl), BMI: 22. Weight: 60,5(fl),60,9(pl), referrals and patients at the university treatment centers. Objective Binges/w: 5,7(fl); 3,2(pl) + difference statistically significant. HDRS: 11(fl); 11,8 (pl)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Fluoxetine plus nutritional counselling program versus nutritional counselling progra plus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Remission<BR/>Relapse (3 months)<BR/>Change in bulimic symptoms<BR/>Drop-outs to side effects and any cause<BR/>Depression (HDRS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Walsh-1997">
<CHAR_METHODS>
<P>RCT, 16 weeks, single blind placebo wash out run-in,diary, interviewers blinded to treatment, ITT analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>BN DSM-III-R+ 1 year + vomiting(purging type). 18-45 years old, mean=26, 80-120% ideal weight, BMI=21.9, through advertisements, duration of illness=7,91, binges/week baseline:7,43, BDI= 13.4</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Desipramine 200 mg till 300 mg followed by fluoxetine 60 mg if not improved versus CBT or SPT or combinations= CBT + med, CBT + Pl, SPT + med, SPT + pl, med. CBT derived from Fairburn, 20 sessions. Medication: desi for 8 weeks. If not better, fluoxetine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Remission<BR/>Change in bulimic symptoms<BR/>Depression: BDI</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-02-25 12:12:52 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Agras-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT comparing antidepressant with placebo. No psychological treatment or combination control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Alger-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT comparing antidepressant with placebo. No psychological treatment or combination control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Barlow-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT comparing antidepressant with placebo. No psychological treatment or combination control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Blouin-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT comparing antidepressant with placebo. No psychological treatment or combination control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Box-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not BN patients, antidepressant versus placebo. No psychological treatment or combination control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-FBNCSG-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT comparing antidepressant with placebo. No psychological treatment or combination control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fichter-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>No antidepressant alone group. Fluoxetine + placebo versus psychotherapy plus placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Horne-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT comparing antidepressant with placebo. No psychological treatment or combination control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hughes-1986-a">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT comparing antidepressant with placebo. No psychological treatment or combination control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kanerva-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT comparing antidepressant with placebo. No psychological treatment or combination control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kennedy-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT comparing antidepressant with placebo. No psychological treatment or combination control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kennedy-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>No psychotherapy control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kennedy-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>No psychotherapy control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Marcus-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Antidepressant plus behaviour modification versus placebo plus behaviour modification. No separate data for BN patients provided by the author.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-25 12:12:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Margittai-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-25 12:12:52 +0000" MODIFIED_BY="[Empty name]">
<P>Subset of <LINK REF="STD-Barlow-1988" TYPE="STUDY">Barlow 1988</LINK>: RCT comparing antidepressant with placebo. No psychological treatment or combination control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McCann-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT comparing antidepressant with placebo. No psychological treatment or combination control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mitchell-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT comparing antidepressant with placebo. No psychological treatment or combination control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-25 12:12:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mitchell-1987-b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-25 12:12:52 +0000" MODIFIED_BY="[Empty name]">
<P>Subset of <LINK REF="STD-Mitchell-1990" TYPE="STUDY">Mitchell 1990</LINK>. Sex-month follow-up maintenance data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pope-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT comparing antidepressant with placebo. No psychological treatment or combination control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pope-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT comparing antidepressant with placebo. No psychological treatment or combination control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Price-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT. No psychological treatment or combination control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rothschild-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT comparing antidepressant with placebo. No psychological treatment or combination control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sabine-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT comparing antidepressant with placebo. No psychological treatment or combination control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Scrimali-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT comparing antidepressant with diet. No psychological treatment or combination control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Walsh-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Subset of Walsh 1988: RCT comparing antidepressant with placebo. No psychological treatment or combination control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Walsh-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Subset of Walsh 1988: RCT comparing antidepressant with placebo. No psychological treatment or combination control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Walsh-1991-a">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT comparing antidepressant with placebo. No psychological treatment or combination control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wheadon-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT comparing antidepressant with placebo. No psychological treatment or combination control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Agras-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Fichter-1991-a">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Goldbloom-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Leitenberg-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Mitchell-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Russell-1995-b">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Walsh-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Antidepressants versus psychological treatments</NAME>
<DICH_OUTCOME CHI2="13.399079429683198" CI_END="1.7674823158816564" CI_START="0.9022437667252122" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2628142786258267" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="69" I2="70.14720286575259" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.24735507726190184" LOG_CI_START="-0.04467610964107433" LOG_EFFECT_SIZE="0.10133948381041379" METHOD="MH" NO="1" P_CHI2="0.009481830556464677" P_Q="0.0" P_Z="0.1737420995868702" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0899343168357251" TOTALS="YES" TOTAL_1="124" TOTAL_2="113" WEIGHT="99.99999999999999" Z="1.360277582587647">
<NAME>Remission</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="2.615834970141197" CI_START="0.6881433519283828" EFFECT_SIZE="1.3416666666666666" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.4176103414038292" LOG_CI_START="-0.16232108143537938" LOG_EFFECT_SIZE="0.12764462998422485" ORDER="1527" O_E="0.0" SE="0.3406545884825923" STUDY_ID="STD-Agras-1992" TOTAL_1="12" TOTAL_2="23" VAR="0.1160455486542443" WEIGHT="14.28594260401422"/>
<DICH_DATA CI_END="1.2369802466780624" CI_START="0.7984090458698538" EFFECT_SIZE="0.9937888198757764" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="21" LOG_CI_END="0.09236276444139759" LOG_CI_START="-0.09777455119324749" LOG_EFFECT_SIZE="-0.002705893375924934" ORDER="1528" O_E="0.0" SE="0.1116876003986823" STUDY_ID="STD-Goldbloom-1996" TOTAL_1="23" TOTAL_2="24" VAR="0.012474120082815739" WEIGHT="28.73412215355781"/>
<DICH_DATA CI_END="8.51545533314101" CI_START="1.0569017918481944" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="0.9302078752444245" LOG_CI_START="0.024034634194900192" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1529" O_E="0.0" SE="0.5322906474223771" STUDY_ID="STD-Leitenberg-1994" TOTAL_1="7" TOTAL_2="7" VAR="0.2833333333333333" WEIGHT="7.883395559833588"/>
<DICH_DATA CI_END="2.3809346662570556" CI_START="1.1666753469319588" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="17" LOG_CI_END="0.37674747836441913" LOG_CI_START="0.06695002086829364" LOG_EFFECT_SIZE="0.22184874961635637" ORDER="1530" O_E="0.0" SE="0.18197656005537105" STUDY_ID="STD-Mitchell-1990" TOTAL_1="54" TOTAL_2="34" VAR="0.03311546840958606" WEIGHT="23.914032276496002"/>
<DICH_DATA CI_END="1.296315377399878" CI_START="0.6814061849808071" EFFECT_SIZE="0.9398496240601504" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="19" LOG_CI_END="0.11271067283240642" LOG_CI_START="-0.1665939287504652" LOG_EFFECT_SIZE="-0.026941627959029376" ORDER="1531" O_E="0.0" SE="0.1640649055498546" STUDY_ID="STD-Walsh-1997" TOTAL_1="28" TOTAL_2="25" VAR="0.026917293233082708" WEIGHT="25.182507406098374"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="37.764265975213235" CI_START="0.9532821324695883" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="1.5770810477247645" LOG_CI_START="-0.02077854695747745" LOG_EFFECT_SIZE="0.7781512503836436" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.05626347349915768" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="7" TOTAL_2="7" WEIGHT="100.0" Z="1.908989288361159">
<NAME>Cinical improvement</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="37.764265975213235" CI_START="0.9532821324695883" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.5770810477247645" LOG_CI_START="-0.02077854695747745" LOG_EFFECT_SIZE="0.7781512503836436" ORDER="1532" O_E="0.0" SE="0.938590635448906" STUDY_ID="STD-Leitenberg-1994" TOTAL_1="7" TOTAL_2="7" VAR="0.8809523809523812" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.174738626764226" CI_END="4.347784491930554" CI_START="1.0912574189033415" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="2.1781992752299115" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="15" I2="28.13921377575552" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.6382680091297745" LOG_CI_START="0.037927209270630154" LOG_EFFECT_SIZE="0.3380976092002024" METHOD="MH" NO="3" P_CHI2="0.24320335754640943" P_Q="0.0" P_Z="0.027271480584486845" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.14108635405785339" TOTALS="YES" TOTAL_1="96" TOTAL_2="88" WEIGHT="100.0" Z="2.207609869084266">
<NAME>Dropouts</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="49.50428593591521" CI_START="0.6678714655696764" EFFECT_SIZE="5.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.6946428005040732" LOG_CI_START="-0.17530711112481204" LOG_EFFECT_SIZE="0.7596678446896304" ORDER="1533" O_E="0.0" SE="1.098417834492155" STUDY_ID="STD-Agras-1992" TOTAL_1="12" TOTAL_2="23" VAR="1.2065217391304348" WEIGHT="9.227994192899212"/>
<DICH_DATA CI_END="2.513997837268053" CI_START="0.5481595143876242" EFFECT_SIZE="1.173913043478261" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.4003648997369897" LOG_CI_START="-0.26109304345420076" LOG_EFFECT_SIZE="0.06963592814139447" ORDER="1534" O_E="0.0" SE="0.38854367010013074" STUDY_ID="STD-Goldbloom-1996" TOTAL_1="23" TOTAL_2="24" VAR="0.15096618357487923" WEIGHT="42.58041980749334"/>
<DICH_DATA CI_END="27.410901151648815" CI_START="0.5837093757509528" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.4379233134948128" LOG_CI_START="-0.23380333083888805" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="1535" O_E="0.0" SE="0.9819805060619657" STUDY_ID="STD-Leitenberg-1994" TOTAL_1="7" TOTAL_2="7" VAR="0.9642857142857144" WEIGHT="11.250256826989297"/>
<DICH_DATA CI_END="6.8905070430105715" CI_START="1.2174042031418575" EFFECT_SIZE="2.8962962962962964" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="5" LOG_CI_END="0.8382511809612355" LOG_CI_START="0.08543479684048577" LOG_EFFECT_SIZE="0.46184298890086073" ORDER="1536" O_E="0.0" SE="0.44220807053373" STUDY_ID="STD-Mitchell-1990" TOTAL_1="54" TOTAL_2="34" VAR="0.19554797764516435" WEIGHT="36.94132917261815"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="5.136822968667492" CI_END="0.6957771916159499" CI_START="-0.26223628431199497" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.21677045365197747" ESTIMABLE="YES" I2="41.59814308768735" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="0.1620483527717016" P_Q="1.0" P_Z="0.3750976744846689" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.09500043530065602" TOTALS="YES" TOTAL_1="66" TOTAL_2="77" UNITS="" WEIGHT="100.0" Z="0.88696514766404">
<NAME>Difference in bulimic symptoms</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_DATA CI_END="0.678742449690308" CI_START="-0.7172007911153656" EFFECT_SIZE="-0.01922917071252883" ESTIMABLE="YES" MEAN_1="2.7" MEAN_2="2.8" ORDER="1537" SD_1="2.8" SD_2="5.9" SE="0.35611451328103366" STUDY_ID="STD-Agras-1992" TOTAL_1="12" TOTAL_2="23" WEIGHT="26.927145261810317"/>
<CONT_DATA CI_END="0.8760767780481762" CI_START="-0.28668851286454194" EFFECT_SIZE="0.29469413259181715" ESTIMABLE="YES" MEAN_1="22.52" MEAN_2="15.91" ORDER="1538" SD_1="24.0" SD_2="19.9" SE="0.2966292493342894" STUDY_ID="STD-Goldbloom-1996" TOTAL_1="23" TOTAL_2="23" WEIGHT="32.64083468216433"/>
<CONT_DATA CI_END="4.216094256239311" CI_START="0.2921071040518086" EFFECT_SIZE="2.2541006801455596" ESTIMABLE="YES" MEAN_1="8.17" MEAN_2="0.08" ORDER="1539" SD_1="5.96" SD_2="0.2" SE="1.0010355249227567" STUDY_ID="STD-Leitenberg-1994" TOTAL_1="3" TOTAL_2="6" WEIGHT="5.4444211359509325"/>
<CONT_DATA CI_END="0.5479853021986568" CI_START="-0.5306365158671175" EFFECT_SIZE="0.008674393165769637" ESTIMABLE="YES" MEAN_1="2.59" MEAN_2="2.56" ORDER="1540" SD_1="3.5" SD_2="3.3" SE="0.2751636832548469" STUDY_ID="STD-Walsh-1997" TOTAL_1="28" TOTAL_2="25" WEIGHT="34.98759892007442"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.661399635068795" CI_END="0.8915112940996505" CI_START="-0.2876746745290565" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.301918309785297" ESTIMABLE="YES" I2="45.37608020593957" I2_Q="0.0" ID="CMP-001.05" NO="5" P_CHI2="0.16030142353999155" P_Q="1.0" P_Z="0.31554407546607965" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.11843409772700783" TOTALS="YES" TOTAL_1="54" TOTAL_2="55" UNITS="" WEIGHT="100.00000000000001" Z="1.0036568093505098">
<NAME>Difference in depression</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_DATA CI_END="0.6735388882552762" CI_START="-0.47107952749289805" EFFECT_SIZE="0.10122968038118907" ESTIMABLE="YES" MEAN_1="17.04" MEAN_2="15.63" ORDER="1541" SD_1="12.8" SD_2="14.5" SE="0.2919998593792483" STUDY_ID="STD-Goldbloom-1996" TOTAL_1="23" TOTAL_2="24" WEIGHT="44.424406456918135"/>
<CONT_DATA CI_END="3.810345809787381" CI_START="0.12694588200215873" EFFECT_SIZE="1.9686458458947698" ESTIMABLE="YES" MEAN_1="21.0" MEAN_2="8.17" ORDER="1542" SD_1="10.44" SD_2="1.84" SE="0.9396601051956593" STUDY_ID="STD-Leitenberg-1994" TOTAL_1="3" TOTAL_2="6" WEIGHT="9.036555537783139"/>
<CONT_DATA CI_END="0.7102114631489" CI_START="-0.37049730789637136" EFFECT_SIZE="0.1698570776262643" ESTIMABLE="YES" MEAN_1="8.2" MEAN_2="6.8" ORDER="1543" SD_1="9.0" SD_2="7.0" SE="0.27569607900190113" STUDY_ID="STD-Walsh-1997" TOTAL_1="28" TOTAL_2="25" WEIGHT="46.53903800529873"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Antidepressants versus combination of antidepressants and psychotherapy</NAME>
<DICH_OUTCOME CHI2="4.818876119601902" CI_END="1.9122794791738695" CI_START="0.9846700182951749" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3722114522709763" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="41" I2="37.744820046383836" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.28155136461007646" LOG_CI_START="-0.006709285485821235" LOG_EFFECT_SIZE="0.13742103956212767" METHOD="MH" NO="1" P_CHI2="0.18555073136052247" P_Q="0.0" P_Z="0.06166074927341222" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.043458873220458154" TOTALS="YES" TOTAL_1="70" TOTAL_2="71" WEIGHT="100.0" Z="1.8687274046611686">
<NAME>Remission</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="4.444932111094823" CI_START="0.688986900914822" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.6478651322349035" LOG_CI_START="-0.16178903486231475" LOG_EFFECT_SIZE="0.24303804868629442" ORDER="1544" O_E="0.0" SE="0.47559486560567094" STUDY_ID="STD-Agras-1992" TOTAL_1="12" TOTAL_2="12" VAR="0.22619047619047622" WEIGHT="10.632773208601987"/>
<DICH_DATA CI_END="1.3996033794209057" CI_START="0.8588941814049729" EFFECT_SIZE="1.0964083175803403" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="23" LOG_CI_END="0.14600498244053411" LOG_CI_START="-0.06606033938503098" LOG_EFFECT_SIZE="0.03997232152775154" ORDER="1545" O_E="0.0" SE="0.12456821978060996" STUDY_ID="STD-Goldbloom-1996" TOTAL_1="23" TOTAL_2="29" VAR="0.015517241379310348" WEIGHT="48.61494178771813"/>
<DICH_DATA CI_END="4.796982630580869" CI_START="0.9572343884300971" EFFECT_SIZE="2.142857142857143" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.6809681459296163" LOG_CI_START="-0.018981707846767504" LOG_EFFECT_SIZE="0.3309932190414244" ORDER="1546" O_E="0.0" SE="0.4111540089159037" STUDY_ID="STD-Leitenberg-1994" TOTAL_1="7" TOTAL_2="7" VAR="0.169047619047619" WEIGHT="13.491918988134556"/>
<DICH_DATA CI_END="2.430354004930639" CI_START="0.9177928983270569" EFFECT_SIZE="1.4935064935064934" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="11" LOG_CI_END="0.38566953746265575" LOG_CI_START="-0.037255307100396214" LOG_EFFECT_SIZE="0.17420711518112977" ORDER="1547" O_E="0.0" SE="0.24842814720808107" STUDY_ID="STD-Walsh-1997" TOTAL_1="28" TOTAL_2="23" VAR="0.06171654432524" WEIGHT="27.260366015545323"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.955183529843845" CI_START="0.8072354890407164" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.695059744496845" LOG_CI_START="-0.0929997531688827" LOG_EFFECT_SIZE="0.3010299956639812" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.13429725751746735" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="7" TOTAL_2="7" WEIGHT="100.0" Z="1.4973690476804995">
<NAME>Cinical improvement</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="4.955183529843845" CI_START="0.8072354890407164" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.695059744496845" LOG_CI_START="-0.0929997531688827" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="1548" O_E="0.0" SE="0.46291004988627577" STUDY_ID="STD-Leitenberg-1994" TOTAL_1="7" TOTAL_2="7" VAR="0.2142857142857143" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.034464520036221" CI_END="2.053028880580284" CI_START="0.6876543307765746" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1881810472063654" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="34" I2="40.41074302816983" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.3123950587658331" LOG_CI_START="-0.16262981752263725" LOG_EFFECT_SIZE="0.07488262062159791" METHOD="MH" NO="3" P_CHI2="0.16929099516161328" P_Q="0.0" P_Z="0.5366182147675683" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.12102336255313408" TOTALS="YES" TOTAL_1="96" TOTAL_2="100" WEIGHT="100.0" Z="0.6179349621984024">
<NAME>Dropouts</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="3.9984381579173807" CI_START="0.2500976532599064" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6018903833636786" LOG_CI_START="-0.6018903833636786" LOG_EFFECT_SIZE="0.0" ORDER="1549" O_E="0.0" SE="0.7071067811865475" STUDY_ID="STD-Agras-1992" TOTAL_1="12" TOTAL_2="12" VAR="0.49999999999999994" WEIGHT="12.537183218056807"/>
<DICH_DATA CI_END="1.3003095752683296" CI_START="0.3868464508046741" EFFECT_SIZE="0.7092391304347826" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" LOG_CI_END="0.1140467606338169" LOG_CI_START="-0.41246138330429033" LOG_EFFECT_SIZE="-0.1492073113352367" ORDER="1550" O_E="0.0" SE="0.3092734900065899" STUDY_ID="STD-Goldbloom-1996" TOTAL_1="23" TOTAL_2="29" VAR="0.09565009162085623" WEIGHT="35.93372205517267"/>
<DICH_DATA CI_END="7.603719398705336" CI_START="0.5260583393807338" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.881026081649161" LOG_CI_START="-0.27896609032119846" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="1551" O_E="0.0" SE="0.681385143869247" STUDY_ID="STD-Leitenberg-1994" TOTAL_1="7" TOTAL_2="7" VAR="0.46428571428571436" WEIGHT="13.302174845933624"/>
<DICH_DATA CI_END="2.99301086723374" CI_START="0.9697947781580969" EFFECT_SIZE="1.7037037037037037" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="13" LOG_CI_END="0.47610829370991364" LOG_CI_START="-0.013320158664740036" LOG_EFFECT_SIZE="0.23139406752258676" ORDER="1552" O_E="0.0" SE="0.28749269563478375" STUDY_ID="STD-Mitchell-1990" TOTAL_1="54" TOTAL_2="52" VAR="0.0826520500433544" WEIGHT="38.22691988083689"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="3.5649959918464913" CI_END="0.7302385407380537" CI_START="-0.04622244994339242" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.34200804539733065" ESTIMABLE="YES" I2="15.848432737054814" I2_Q="0.0" ID="CMP-002.04" NO="4" P_CHI2="0.3124298366988514" P_Q="1.0" P_Z="0.08423736037653377" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0260253015807174" TOTALS="YES" TOTAL_1="67" TOTAL_2="69" UNITS="" WEIGHT="100.0" Z="1.726612049920013">
<NAME>Difference in bulimic symptoms</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_DATA CI_END="0.9005828007805134" CI_START="-0.7009133332187232" EFFECT_SIZE="0.09983473378089512" ESTIMABLE="YES" MEAN_1="2.7" MEAN_2="2.3" ORDER="1553" SD_1="2.8" SD_2="4.7" SE="0.4085524393896096" STUDY_ID="STD-Agras-1992" TOTAL_1="12" TOTAL_2="12" WEIGHT="20.335738169205175"/>
<CONT_DATA CI_END="0.6337229602760374" CI_START="-0.4613222583763886" EFFECT_SIZE="0.08620035094982438" ESTIMABLE="YES" MEAN_1="22.52" MEAN_2="20.34" ORDER="1554" SD_1="24.0" SD_2="25.6" SE="0.27935340324873387" STUDY_ID="STD-Goldbloom-1996" TOTAL_1="23" TOTAL_2="29" WEIGHT="37.70371619883539"/>
<CONT_DATA CI_END="2.964420122740118" CI_START="-0.1764542252488015" EFFECT_SIZE="1.3939829487456583" ESTIMABLE="YES" MEAN_1="9.16" MEAN_2="2.4" ORDER="1555" SD_1="4.93" SD_2="3.78" SE="0.8012581794266975" STUDY_ID="STD-Leitenberg-1994" TOTAL_1="4" TOTAL_2="5" WEIGHT="5.873279396945239"/>
<CONT_DATA CI_END="1.1381688518659203" CI_START="0.010893894939914883" EFFECT_SIZE="0.5745313734029176" ESTIMABLE="YES" MEAN_1="2.59" MEAN_2="0.95" ORDER="1556" SD_1="3.5" SD_2="1.6" SE="0.28757542633890376" STUDY_ID="STD-Walsh-1997" TOTAL_1="28" TOTAL_2="23" WEIGHT="36.087266235014205"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.5835500602558867" CI_END="0.6198575844316114" CI_START="-0.1359842437648896" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.24193667033336091" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.05" NO="5" P_CHI2="0.4530400873490751" P_Q="1.0" P_Z="0.20957830345570472" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="54" TOTAL_2="57" UNITS="" WEIGHT="100.0" Z="1.2547259034985563">
<NAME>Difference in depression</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_DATA CI_END="0.544871149698183" CI_START="-0.5496319749181854" EFFECT_SIZE="-0.0023804126100012276" ESTIMABLE="YES" MEAN_1="17.04" MEAN_2="17.07" ORDER="1557" SD_1="12.8" SD_2="12.1" SE="0.2792151114126763" STUDY_ID="STD-Goldbloom-1996" TOTAL_1="23" TOTAL_2="29" WEIGHT="47.69005602365952"/>
<CONT_DATA CI_END="1.6675546904039589" CI_START="-1.21223529230799" EFFECT_SIZE="0.2276596990479844" ESTIMABLE="YES" MEAN_1="21.0" MEAN_2="18.2" ORDER="1558" SD_1="10.44" SD_2="10.82" SE="0.7346538011482263" STUDY_ID="STD-Leitenberg-1994" TOTAL_1="3" TOTAL_2="5" WEIGHT="6.888746616413734"/>
<CONT_DATA CI_END="1.061376106051838" CI_START="-0.0601299749836377" EFFECT_SIZE="0.5006230655341002" ESTIMABLE="YES" MEAN_1="8.2" MEAN_2="4.4" ORDER="1559" SD_1="9.0" SD_2="5.0" SE="0.2861037472835656" STUDY_ID="STD-Walsh-1997" TOTAL_1="28" TOTAL_2="23" WEIGHT="45.421197359926744"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Psychotherapy versus combination of psychotherapy and antidepressants</NAME>
<DICH_OUTCOME CHI2="3.510175224052466" CI_END="1.4455615277187825" CI_START="1.0170026651886277" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2124932685933338" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="64" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.16003658136127683" LOG_CI_START="0.007322091049782531" LOG_EFFECT_SIZE="0.08367933620552971" METHOD="MH" NO="1" P_CHI2="0.6218486804849783" P_Q="0.0" P_Z="0.031720911265293604" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="132" TOTAL_2="125" WEIGHT="100.0" Z="2.147909931513715">
<NAME>Remission</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="4.074851195304276" CI_START="0.70560522509616" EFFECT_SIZE="1.6956521739130435" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" LOG_CI_END="0.6101117538764363" LOG_CI_START="-0.15143821185862372" LOG_EFFECT_SIZE="0.22933677100890631" ORDER="1560" O_E="0.0" SE="0.4473382196059022" STUDY_ID="STD-Agras-1992" TOTAL_1="23" TOTAL_2="12" VAR="0.20011148272017837" WEIGHT="4.021274206775445"/>
<DICH_DATA CI_END="1.8162883004494357" CI_START="0.8340046561074324" EFFECT_SIZE="1.2307692307692308" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.2591847854607726" LOG_CI_START="-0.07883152476259651" LOG_EFFECT_SIZE="0.09017663034908804" ORDER="1561" O_E="0.0" SE="0.1985524538329278" STUDY_ID="STD-Fichter-1991-a" TOTAL_1="20" TOTAL_2="20" VAR="0.03942307692307692" WEIGHT="20.411982187803247"/>
<DICH_DATA CI_END="1.401998093568171" CI_START="0.8681784603686515" EFFECT_SIZE="1.1032608695652173" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.1467474230790091" LOG_CI_START="-0.06139099327165624" LOG_EFFECT_SIZE="0.04267821490367641" ORDER="1562" O_E="0.0" SE="0.12226153606615825" STUDY_ID="STD-Goldbloom-1996" TOTAL_1="24" TOTAL_2="29" VAR="0.014947883201256514" WEIGHT="53.83391970005494"/>
<DICH_DATA CI_END="2.8432093444070508" CI_START="0.15631787554395965" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.453808837802866" LOG_CI_START="-0.8059913559142284" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="1563" O_E="0.0" SE="0.7400128699009549" STUDY_ID="STD-Leitenberg-1994" TOTAL_1="7" TOTAL_2="7" VAR="0.5476190476190477" WEIGHT="1.469457915024966"/>
<DICH_DATA CI_END="2.6201315370150087" CI_START="0.684689336982298" EFFECT_SIZE="1.3393939393939394" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.4183230945128114" LOG_CI_START="-0.16450643557040265" LOG_EFFECT_SIZE="0.1269083294712044" ORDER="1564" O_E="0.0" SE="0.3423569510235834" STUDY_ID="STD-Russell-1995-b" TOTAL_1="33" TOTAL_2="34" VAR="0.11720828191416427" WEIGHT="6.865582626077188"/>
<DICH_DATA CI_END="2.5689644591715473" CI_START="0.9829680236875346" EFFECT_SIZE="1.589090909090909" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" LOG_CI_END="0.40975809597812146" LOG_CI_START="-0.007460609697803073" LOG_EFFECT_SIZE="0.20114874314015918" ORDER="1565" O_E="0.0" SE="0.24507633297993933" STUDY_ID="STD-Walsh-1997" TOTAL_1="25" TOTAL_2="23" VAR="0.060062408986894106" WEIGHT="13.397783364264216"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5509814452732644" CI_END="2.65948837881752" CI_START="0.30414581979280186" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8993732668947217" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" I2="35.5246961175727" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.4247980969215168" LOG_CI_START="-0.5169181481420249" LOG_EFFECT_SIZE="-0.04606002561025397" METHOD="MH" NO="2" P_CHI2="0.21299109524751525" P_Q="0.0" P_Z="0.847956428039853" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.31156688869619115" TOTALS="YES" TOTAL_1="27" TOTAL_2="27" WEIGHT="99.99999999999999" Z="0.19172652440969418">
<NAME>Cinical improvement</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="2.113012012857777" CI_START="0.681491629596771" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.3249019661024858" LOG_CI_START="-0.16653947400723618" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="1566" O_E="0.0" SE="0.2886751345948129" STUDY_ID="STD-Fichter-1991-a" TOTAL_1="20" TOTAL_2="20" VAR="0.08333333333333336" WEIGHT="77.48684007619268"/>
<DICH_DATA CI_END="2.4780570510202113" CI_START="0.04483799558422871" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.3941113006913962" LOG_CI_START="-1.3483538101307213" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="1567" O_E="0.0" SE="1.023532631438318" STUDY_ID="STD-Leitenberg-1994" TOTAL_1="7" TOTAL_2="7" VAR="1.0476190476190477" WEIGHT="22.51315992380731"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4545511188156324" CI_END="0.8797349355222615" CI_START="0.37510971175806257" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5744537562652483" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="46" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-0.05564816123681174" LOG_CI_START="-0.4258416916255081" LOG_EFFECT_SIZE="-0.24074492643115988" METHOD="MH" NO="3" P_CHI2="0.9182542809451172" P_Q="0.0" P_Z="0.010796582548669737" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="141" TOTAL_2="154" WEIGHT="99.99999999999999" Z="2.5492146487291834">
<NAME>Dropouts</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="1.4972940925796658" CI_START="0.020200271170349372" EFFECT_SIZE="0.17391304347826086" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.1753071111248121" LOG_CI_START="-1.6946428005040732" LOG_EFFECT_SIZE="-0.7596678446896306" ORDER="1568" O_E="0.0" SE="1.098417834492155" STUDY_ID="STD-Agras-1992" TOTAL_1="23" TOTAL_2="12" VAR="1.2065217391304348" WEIGHT="3.9192024852081544"/>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="1569" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Fichter-1991-a" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="1.8389011660668693"/>
<DICH_DATA CI_END="1.1619734137130473" CI_START="0.3141357253129486" EFFECT_SIZE="0.6041666666666666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="0.06519619138494193" LOG_CI_START="-0.5028826703382043" LOG_EFFECT_SIZE="-0.21884323947663117" ORDER="1570" O_E="0.0" SE="0.3336923354118936" STUDY_ID="STD-Goldbloom-1996" TOTAL_1="24" TOTAL_2="29" VAR="0.11135057471264369" WEIGHT="42.465905637761736"/>
<DICH_DATA CI_END="4.334593955143529" CI_START="0.05767552914693294" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6369484210048898" LOG_CI_START="-1.2390084123328524" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="1571" O_E="0.0" SE="1.1019463300386796" STUDY_ID="STD-Leitenberg-1994" TOTAL_1="7" TOTAL_2="7" VAR="1.2142857142857144" WEIGHT="3.894143645788665"/>
<DICH_DATA CI_END="1.5005284091949647" CI_START="0.23059927364608535" EFFECT_SIZE="0.5882352941176471" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="0.176244222246584" LOG_CI_START="-0.6371420650031319" LOG_EFFECT_SIZE="-0.2304489213782739" ORDER="1572" O_E="0.0" SE="0.4777871314575408" STUDY_ID="STD-Mitchell-1990" TOTAL_1="34" TOTAL_2="52" VAR="0.22828054298642536" WEIGHT="20.71399925984428"/>
<DICH_DATA CI_END="1.4852074736507261" CI_START="0.2894366601006495" EFFECT_SIZE="0.6556473829201102" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.17178712595481047" LOG_CI_START="-0.5384464619140116" LOG_EFFECT_SIZE="-0.1833296679796006" ORDER="1573" O_E="0.0" SE="0.41719472522710677" STUDY_ID="STD-Russell-1995-b" TOTAL_1="33" TOTAL_2="34" VAR="0.1740514387573211" WEIGHT="27.167847805330286"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="7.874753360958587" CI_END="0.4554549941527721" CI_START="-0.21134665327015717" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.12205417044130745" ESTIMABLE="YES" I2="36.50594792226795" I2_Q="0.0" ID="CMP-003.04" NO="4" P_CHI2="0.16327472855412728" P_Q="1.0" P_Z="0.4730532700856912" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.06117628951817666" TOTALS="YES" TOTAL_1="129" TOTAL_2="118" UNITS="" WEIGHT="99.99999999999999" Z="0.7175200575836183">
<NAME>Difference in bulimic symptoms</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_DATA CI_END="0.7866621057979509" CI_START="-0.6099399687741539" EFFECT_SIZE="0.0883610685118985" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="2.3" ORDER="1574" SD_1="5.9" SD_2="4.7" SE="0.35628258620778847" STUDY_ID="STD-Agras-1992" TOTAL_1="23" TOTAL_2="12" WEIGHT="15.382149489392564"/>
<CONT_DATA CI_END="1.2322538249931974" CI_START="-0.05349160972810507" EFFECT_SIZE="0.5893811076325461" ESTIMABLE="YES" MEAN_1="6.6" MEAN_2="3.0" ORDER="1575" SD_1="6.94" SD_2="4.77" SE="0.32800231148712383" STUDY_ID="STD-Fichter-1991-a" TOTAL_1="20" TOTAL_2="19" WEIGHT="17.146006773142407"/>
<CONT_DATA CI_END="0.36098752855825833" CI_START="-0.7360808805408473" EFFECT_SIZE="-0.18754667599129451" ESTIMABLE="YES" MEAN_1="15.91" MEAN_2="20.34" ORDER="1576" SD_1="19.9" SD_2="25.6" SE="0.27986953274464255" STUDY_ID="STD-Goldbloom-1996" TOTAL_1="23" TOTAL_2="29" WEIGHT="20.742105811668758"/>
<CONT_DATA CI_END="1.0015381471192049" CI_START="-2.326234589315269" EFFECT_SIZE="-0.6623482210980319" ESTIMABLE="YES" MEAN_1="0.33" MEAN_2="4.0" ORDER="1577" SD_1="5.0" SD_2="3.78" SE="0.848937215857924" STUDY_ID="STD-Leitenberg-1994" TOTAL_1="6" TOTAL_2="2" WEIGHT="3.7008563157160395"/>
<CONT_DATA CI_END="0.3126696367966123" CI_START="-0.6618295478712511" EFFECT_SIZE="-0.17457995553731945" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="1.2" ORDER="1578" SD_1="1.7" SD_2="2.7" SE="0.24860129888982366" STUDY_ID="STD-Russell-1995-b" TOTAL_1="32" TOTAL_2="33" WEIGHT="23.529167818531523"/>
<CONT_DATA CI_END="1.1526646459520316" CI_START="-0.004976920654272354" EFFECT_SIZE="0.5738438626488797" ESTIMABLE="YES" MEAN_1="2.56" MEAN_2="0.95" ORDER="1579" SD_1="3.5" SD_2="1.6" SE="0.2953221527889372" STUDY_ID="STD-Walsh-1997" TOTAL_1="25" TOTAL_2="23" WEIGHT="19.499713791548704"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.9262443572636885" CI_END="0.5334512226868908" CI_START="-0.266658290977761" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.13339646585456488" ESTIMABLE="YES" I2="49.53473776853271" I2_Q="0.0" ID="CMP-003.05" NO="5" P_CHI2="0.09431767345486985" P_Q="1.0" P_Z="0.5134074368807944" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.09854721306410755" TOTALS="YES" TOTAL_1="107" TOTAL_2="110" UNITS="" WEIGHT="99.99999999999997" Z="0.6535412072339293">
<NAME>Difference in depression</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_DATA CI_END="1.0681549018754257" CI_START="-0.20383045359059593" EFFECT_SIZE="0.4321622241424149" ESTIMABLE="YES" MEAN_1="11.1" MEAN_2="8.3" ORDER="1580" SD_1="7.4" SD_2="5.0" SE="0.32449202268492683" STUDY_ID="STD-Fichter-1991-a" TOTAL_1="20" TOTAL_2="19" WEIGHT="20.438471541030715"/>
<CONT_DATA CI_END="0.36098752855825833" CI_START="-0.7360808805408473" EFFECT_SIZE="-0.18754667599129451" ESTIMABLE="YES" MEAN_1="15.91" MEAN_2="20.34" ORDER="1581" SD_1="19.9" SD_2="25.6" SE="0.27986953274464255" STUDY_ID="STD-Goldbloom-1996" TOTAL_1="23" TOTAL_2="29" WEIGHT="23.5547383507693"/>
<CONT_DATA CI_END="0.10492050219123317" CI_START="-2.602767568701478" EFFECT_SIZE="-1.2489235332551223" ESTIMABLE="YES" MEAN_1="8.17" MEAN_2="18.2" ORDER="1582" SD_1="1.84" SD_2="10.82" SE="0.6907494454619086" STUDY_ID="STD-Leitenberg-1994" TOTAL_1="6" TOTAL_2="5" WEIGHT="7.2370244156918515"/>
<CONT_DATA CI_END="0.7296715208933304" CI_START="-0.2321533018793209" EFFECT_SIZE="0.24875910950700478" ESTIMABLE="YES" MEAN_1="6.8" MEAN_2="5.3" ORDER="1583" SD_1="6.4" SD_2="5.5" SE="0.2453679838913885" STUDY_ID="STD-Russell-1995-b" TOTAL_1="33" TOTAL_2="34" WEIGHT="26.243495654866106"/>
<CONT_DATA CI_END="1.083733845967911" CI_START="-0.06850090925171626" EFFECT_SIZE="0.5076164683580973" ESTIMABLE="YES" MEAN_1="8.2" MEAN_2="4.4" ORDER="1584" SD_1="9.0" SD_2="5.0" SE="0.29394283882466915" STUDY_ID="STD-Walsh-1997" TOTAL_1="25" TOTAL_2="23" WEIGHT="22.526270037642014"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>CBT versus combination of CBT and antidepressants</NAME>
<DICH_OUTCOME CHI2="3.478019599937894" CI_END="1.5973519210807383" CI_START="0.9473935719623138" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.23017110281194" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="41" I2="13.744016852188807" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.20340060840271956" LOG_CI_START="-0.0234695662734276" LOG_EFFECT_SIZE="0.08996552106464598" METHOD="MH" NO="1" P_CHI2="0.3236242331392354" P_Q="0.0" P_Z="0.1200770942627188" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.01275804830712707" TOTALS="YES" TOTAL_1="79" TOTAL_2="71" WEIGHT="100.0" Z="1.5544500848451523">
<NAME>Remission</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="4.074851195304276" CI_START="0.70560522509616" EFFECT_SIZE="1.6956521739130435" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" LOG_CI_END="0.6101117538764363" LOG_CI_START="-0.15143821185862372" LOG_EFFECT_SIZE="0.22933677100890631" ORDER="1585" O_E="0.0" SE="0.4473382196059022" STUDY_ID="STD-Agras-1992" TOTAL_1="23" TOTAL_2="12" VAR="0.20011148272017837" WEIGHT="8.342889885074436"/>
<DICH_DATA CI_END="1.401998093568171" CI_START="0.8681784603686515" EFFECT_SIZE="1.1032608695652173" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.1467474230790091" LOG_CI_START="-0.06139099327165624" LOG_EFFECT_SIZE="0.04267821490367641" ORDER="1586" O_E="0.0" SE="0.12226153606615825" STUDY_ID="STD-Goldbloom-1996" TOTAL_1="24" TOTAL_2="29" VAR="0.014947883201256514" WEIGHT="64.09988621789738"/>
<DICH_DATA CI_END="2.8432093444070508" CI_START="0.15631787554395965" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.453808837802866" LOG_CI_START="-0.8059913559142284" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="1587" O_E="0.0" SE="0.7400128699009549" STUDY_ID="STD-Leitenberg-1994" TOTAL_1="7" TOTAL_2="7" VAR="0.5476190476190477" WEIGHT="3.1691999372547732"/>
<DICH_DATA CI_END="2.5689644591715473" CI_START="0.9829680236875346" EFFECT_SIZE="1.589090909090909" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" LOG_CI_END="0.40975809597812146" LOG_CI_START="-0.007460609697803073" LOG_EFFECT_SIZE="0.20114874314015918" ORDER="1588" O_E="0.0" SE="0.24507633297993933" STUDY_ID="STD-Walsh-1997" TOTAL_1="25" TOTAL_2="23" VAR="0.060062408986894106" WEIGHT="24.388023959773417"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2191761238974703" CI_END="0.9185142547072173" CI_START="0.333984357318279" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5538676674496066" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-0.03691409935529063" LOG_CI_START="-0.4762738735759922" LOG_EFFECT_SIZE="-0.2565939864656414" METHOD="MH" NO="2" P_CHI2="0.748408927136555" P_Q="0.0" P_Z="0.022061450234264843" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="88" TOTAL_2="100" WEIGHT="100.0" Z="2.2893082236044138">
<NAME>Dropouts</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="1.4972940925796658" CI_START="0.020200271170349372" EFFECT_SIZE="0.17391304347826086" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.1753071111248121" LOG_CI_START="-1.6946428005040732" LOG_EFFECT_SIZE="-0.7596678446896306" ORDER="1589" O_E="0.0" SE="1.098417834492155" STUDY_ID="STD-Agras-1992" TOTAL_1="23" TOTAL_2="12" VAR="1.2065217391304348" WEIGHT="5.520528259269501"/>
<DICH_DATA CI_END="1.1619734137130473" CI_START="0.3141357253129486" EFFECT_SIZE="0.6041666666666666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="0.06519619138494193" LOG_CI_START="-0.5028826703382043" LOG_EFFECT_SIZE="-0.21884323947663117" ORDER="1590" O_E="0.0" SE="0.3336923354118936" STUDY_ID="STD-Goldbloom-1996" TOTAL_1="24" TOTAL_2="29" VAR="0.11135057471264369" WEIGHT="59.81682064489825"/>
<DICH_DATA CI_END="4.334593955143529" CI_START="0.05767552914693294" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6369484210048898" LOG_CI_START="-1.2390084123328524" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="1591" O_E="0.0" SE="1.1019463300386796" STUDY_ID="STD-Leitenberg-1994" TOTAL_1="7" TOTAL_2="7" VAR="1.2142857142857144" WEIGHT="5.485230764005629"/>
<DICH_DATA CI_END="1.5005284091949647" CI_START="0.23059927364608535" EFFECT_SIZE="0.5882352941176471" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="0.176244222246584" LOG_CI_START="-0.6371420650031319" LOG_EFFECT_SIZE="-0.2304489213782739" ORDER="1592" O_E="0.0" SE="0.4777871314575408" STUDY_ID="STD-Mitchell-1990" TOTAL_1="34" TOTAL_2="52" VAR="0.22828054298642536" WEIGHT="29.177420331826628"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Classical psychotherapy versus combination of antidepressants and psychotherapy</NAME>
<DICH_OUTCOME CHI2="3.381346828800497" CI_END="1.4441564495667518" CI_START="1.0031618589996583" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2036289580405286" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="54" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.15961424413601386" LOG_CI_START="0.0013710115838552089" LOG_EFFECT_SIZE="0.08049262785993447" METHOD="MH" NO="1" P_CHI2="0.4961477931904854" P_Q="0.0" P_Z="0.04616013688916231" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="99" TOTAL_2="91" WEIGHT="99.99999999999999" Z="1.993926047667874">
<NAME>Remission</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="4.074851195304276" CI_START="0.70560522509616" EFFECT_SIZE="1.6956521739130435" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" LOG_CI_END="0.6101117538764363" LOG_CI_START="-0.15143821185862372" LOG_EFFECT_SIZE="0.22933677100890631" ORDER="1593" O_E="0.0" SE="0.4473382196059022" STUDY_ID="STD-Agras-1992" TOTAL_1="23" TOTAL_2="12" VAR="0.20011148272017837" WEIGHT="4.317710165760249"/>
<DICH_DATA CI_END="1.8162883004494357" CI_START="0.8340046561074324" EFFECT_SIZE="1.2307692307692308" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.2591847854607726" LOG_CI_START="-0.07883152476259651" LOG_EFFECT_SIZE="0.09017663034908804" ORDER="1594" O_E="0.0" SE="0.1985524538329278" STUDY_ID="STD-Fichter-1991-a" TOTAL_1="20" TOTAL_2="20" VAR="0.03942307692307692" WEIGHT="21.916690696471253"/>
<DICH_DATA CI_END="1.401998093568171" CI_START="0.8681784603686515" EFFECT_SIZE="1.1032608695652173" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.1467474230790091" LOG_CI_START="-0.06139099327165624" LOG_EFFECT_SIZE="0.04267821490367641" ORDER="1595" O_E="0.0" SE="0.12226153606615825" STUDY_ID="STD-Goldbloom-1996" TOTAL_1="24" TOTAL_2="29" VAR="0.014947883201256514" WEIGHT="57.80239058555401"/>
<DICH_DATA CI_END="2.8432093444070508" CI_START="0.15631787554395965" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.453808837802866" LOG_CI_START="-0.8059913559142284" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="1596" O_E="0.0" SE="0.7400128699009549" STUDY_ID="STD-Leitenberg-1994" TOTAL_1="7" TOTAL_2="7" VAR="0.5476190476190477" WEIGHT="1.5777818302392765"/>
<DICH_DATA CI_END="2.5689644591715473" CI_START="0.9829680236875346" EFFECT_SIZE="1.589090909090909" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" LOG_CI_END="0.40975809597812146" LOG_CI_START="-0.007460609697803073" LOG_EFFECT_SIZE="0.20114874314015918" ORDER="1597" O_E="0.0" SE="0.24507633297993933" STUDY_ID="STD-Walsh-1997" TOTAL_1="25" TOTAL_2="23" VAR="0.060062408986894106" WEIGHT="14.38542672197521"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3224851496359424" CI_END="0.9010043768694979" CI_START="0.331855614436559" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5468119979445003" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-0.04527309931432884" LOG_CI_START="-0.4790508304305859" LOG_EFFECT_SIZE="-0.2621619648724573" METHOD="MH" NO="2" P_CHI2="0.8575492471545206" P_Q="0.0" P_Z="0.017832187798908924" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="108" TOTAL_2="120" WEIGHT="99.99999999999997" Z="2.369084313959676">
<NAME>Dropouts</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="1.4972940925796658" CI_START="0.020200271170349372" EFFECT_SIZE="0.17391304347826086" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.1753071111248121" LOG_CI_START="-1.6946428005040732" LOG_EFFECT_SIZE="-0.7596678446896306" ORDER="1598" O_E="0.0" SE="1.098417834492155" STUDY_ID="STD-Agras-1992" TOTAL_1="23" TOTAL_2="12" VAR="1.2065217391304348" WEIGHT="5.3811433098018275"/>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="1599" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Fichter-1991-a" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="2.5248480384758576"/>
<DICH_DATA CI_END="1.1619734137130473" CI_START="0.3141357253129486" EFFECT_SIZE="0.6041666666666666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="0.06519619138494193" LOG_CI_START="-0.5028826703382043" LOG_EFFECT_SIZE="-0.21884323947663117" ORDER="1600" O_E="0.0" SE="0.3336923354118936" STUDY_ID="STD-Goldbloom-1996" TOTAL_1="24" TOTAL_2="29" VAR="0.11135057471264369" WEIGHT="58.306536822166905"/>
<DICH_DATA CI_END="4.334593955143529" CI_START="0.05767552914693294" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6369484210048898" LOG_CI_START="-1.2390084123328524" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="1601" O_E="0.0" SE="1.1019463300386796" STUDY_ID="STD-Leitenberg-1994" TOTAL_1="7" TOTAL_2="7" VAR="1.2142857142857144" WEIGHT="5.346737022654757"/>
<DICH_DATA CI_END="1.5005284091949647" CI_START="0.23059927364608535" EFFECT_SIZE="0.5882352941176471" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="0.176244222246584" LOG_CI_START="-0.6371420650031319" LOG_EFFECT_SIZE="-0.2304489213782739" ORDER="1602" O_E="0.0" SE="0.4777871314575408" STUDY_ID="STD-Mitchell-1990" TOTAL_1="34" TOTAL_2="52" VAR="0.22828054298642536" WEIGHT="28.440734806900643"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>